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CHAPTER 1 /
Review of cytotoxic drug penetration and statement of the aims of 
the thesis.
Introduction
The aim of cancer chemotherapy is to eradicate clinically 
manifest or microscopic metastases. There is increasing recognition 
of the fact that poor drug penetration into solid tumours may be an 
important aspect of cytotoxic drug resistance (Sutherland et al, 
1979). Diminished access of chemotherapeutic agents to clonogenic 
cells in tumour nodules may be related to altered vasculature or 
drug penetration barriers. Penetration, therefore, will be 
determined by the concentration of free drug in the tumour vascular 
compartment and subsequent transport barriers interposed between 
the cytotoxic agent and its site of pharmacological action.
The introduction of the multicellular tumour spheroid system 
has proved a useful in vitro model for studying dynamic aspects of 
drug penetration. The use of this model circumvents the problems of 
drug disposition in vivo, but general pharmacokinetic principles 
can still be applied to analyses of the data obtained. The purpose 
of this introductory chapter is to describe
,1. The mode of passage of a drug from its site of administration 
to its site of pharmacological action.
2. The application of pharmacokinetic principles to drug 
penetration.
3. The role of multicellular spheroids as in vitro models for drug 
penetration studies.
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PASSAGE OF DRUG FROM ITS SITE OF ADMINISTRATION TO ITS SITE OF 
PHARMACOLOGICAL ACTION
Once a water soluble drug enters the circulation from its site 
of administration, it becomes rapidly and widely disseminated 
throughout the body, via the blood stream. There will usually be a 
dynamic equilibrium between drug at binding sites, including sites 
of biological action and drug in intracellular or interstitial 
fluid. Further equilibria exist between drug in these compartments 
and free drug in plasma water, implying an indirect relationship 
between measured plasma drug levels and drug concentration at 
receptor sites (fig 1.1).
1.1 Plasma protein binding
Depending on the physico-chemical properties of the cytotoxic 
agent, it will partition to a varying extent, between blood cells, 
plasma protein and plasma water. Plasma protein binding has a 
number of consequences. It will determine the relative amount of 
free drug available for tumour interaction, provide a "store" or 
buffer stabilising sudden alterations in drug availability and is a 
possible site of drug interaction regarding drug displacement 
phenomena.
1.2 Egress from the vascular compartment / 3
There are a number of modes of egress for a cytotoxic drug from 
the circulation. If sufficiently lipid soluble, it can diffuse 
through the capillary endothelial lining into the extracellular 
fluid, whereas small polar compounds can diffuse out through water 
filled pores between capillary endothelial junctions. Specific 
active transport mechanisms exist for a few molecules, e.g. 
hormones, amino acids, and it is possible that cytotoxic drugs could 
compete for these systems.
Malignant tumours appear to derive their vascular supply from 
newly formed vessels and by incorporation of existing vessels from 
host tissues (Papadimitriou and Woods, 1974). The anatomy of the 
tumour microangioarchitecture is altered, with thin walled 
arterioles deficient in medial smooth muscle and adrenergic 
innervation (Mattson and Peterson, 1981). No formal studies of drug 
diffusibility across tumour capillary endothelium have been 
undertaken but it would appear anatomically, if not functionally, 
that they might present a less well defined drug barrier. There is 
some evidence to suggest that tumour cells can participate in and 
be contiguous with the host derived endothelial lining. This 
implies that cytotoxic agents .could exert their effect locally on 
the tumour cells incorporated into the endothelial lining of the 
vessels and alter drug permeability or induce local vascular 
collapse.
In a series of classical experiments Goldacre and Sylven (1962) 
demonstrated that the blood borne dye, lissamine green, did not 
diffuse into central regions of solid murine tumours grown
subcutaneously. Nevertheless, it was possible to regrow these 
tumours from tissue fragments transplanted from the dye-free 
regions. The authors considered that, in the animal tumour model 
studied, there were areas of the tumour vasculature which were not 
contiguous with the host circulation, yet were supportive of tumour 
growth. If the tumour microvasculature is compartmentalised in 
this way, it will lead to marked intratumoural differences in 
drug exposure depending on the ability of the drug in question 
to diffuse or be transported from the peripheral tumour vascular 
ring, in direct continuity with the systemic circulation, into the 
central region of solid tumours, (figures 1.2 and 1.3)
1.3 Diffusion through interstitial fluid /5
Within interstitial fluid, drug can partition between 
interstitial water and protein (consisting of structural proteins 
such as collagen and extravascular plasma proteins). It is possible 
that drug-cell surface interactions could occur with formation of 
ionic, Van der Waals or dipole-dipole bonds. The degree to which 
interstitial water will permeate throughout the tumour will depend 
on the compact "packing" of tumour cells and the tightness of 
intercellular junctions. This varies for different tumour types 
from simple membrane apposition to tight desmosomal junctions 
(Weinstein et al, 1979).
Cell junctions in tumour cells can be grouped into two major 
categories. The first category includes junctions at which surface 
membranes of neighbouring cells come into direct control (eg 
occludentes junction, "gap" or nexus junctions, and probably septate 
desmosomes). These junctions can be further subclassified according 
to differences in the components within the interior of the 
junctional membranes. The second general category includes 
junctions where the surface membranes of adjacent cells are 
separated by a 15 - 35 nm interspace (eg adherentes junctions). 
This interspace typically contains electron-dense proteinaceous 
material. Junctions in this category can be subclassified on the 
basis of the morphology of cytoplasmic and extracellular material 
associated with the membrane at the junction.
Tne primary function of these junctions is complex, and depends 
to a large part on their tissue of origin. They control cell to 
cell adhesion, transepithelial permeability, modulate ionic coupling 
between cells by providing channels across cell membranes and 
metabolically couple cells when nutrients or intermediate 
metabolites of low molecular weight are exchanged by diffusion 
through gap junctions.
1.4 Transcellular drug transport
There are several potential mechanisms whereby a drug molecule 
might pass through cellular membranes to reach the cytoplasm. 
These include diffusion through water filled membrane pores if the 
molecule is small and sufficiently polar to dissolve in water;, 
diffusion of lipophilic drugs through the lipid domain of the cell 
membrane; carrier mediated transport systems which may be either 
passive (governed by drug; concentration gradients) or active 
(coupled to energy expenditure). There is some evidence to suggest 
that adriamycin enters cells by diffusion of the electroneutral 
molecule through the lipid domain of the cell membrane ( Dalmark, 
1981; Dalmark and Storm, 1981; Dalmark, 1982) . The degree of
passive diffusion is determined by - the concentration gradient 
across the membrane; membrane thickness; total surface area of
membrane exposed to drug; duration of drug-cell contact; membrane 
permeability. As previously mentioned, the physico-chemical 
properties of the drug are also important, particularly charge and 
lipid solubility.
There is microheterogeneity of intratumoural pH, related to 
areas of necrosis and hypoxia (Vaupel et al, 1981; Acker et al, 
1982). Basic drugs such as adriamycin (pKa 7.6-8.2), will tend to 
ionise at acidic pH and thus limit their ability to cross lipid 
membranes (fig 1.1). The oil-water partition co-efficient remains a 
useful marker of lipid solubility and will determine the ease with 
which the drug can traverse the lipid portion of the cell membrane. 
Adriamycin has the particular property of self-association to form 
dimeric structures through a It* electron interaction of the
tetracyclic anthraquinone rings (Dalmark, 1981). Because of this 
phenomenon, the kinetics of cell uptake of adriamycin appear to
fulfil the criteria for a carrier mediated, saturable system.
However careful analysis of experimental data derived from Dalmark
(1981) favours the explanation that adriamycin is transported by 
diffusion of the monomer through the cell membrane.
Once in the cytoplasm, the drug may have to cross further
intracellular membranes before reaching its site of pharmacological 
action. In common with other compartments through which the ^ru9 
has diffused, there is a potential for reversible or irreversible 
binding to intracytoplasmic macromolecules, e.g. protein, KNA, 
cytoplasmic membrane systems (fig 1.1).
1.5 Intercellular drug transport /8
Cell-cell transfer of active drug molecules may be accomplished 
by different means. Drug could be transported by specific transport 
or efflux systems, or by simple diffusion through the lipid domain 
of the membrane. The compactness of tumour cells and the number and 
type of intercellular connections would determine whether drug 
passes directly from cell to cell or is first transported into an 
intercellular space. Intercellular channels have been demonstrated 
by electron microscopy after staining with uranyl acetate (Weinstein 
et al, 1979), and this could represent a relatively rapid method of 
drug penetration to the centre of solid nodules (a "snakes and 
ladders" analogy would be appropriate).
Gap junctions are semipermeable intercellular connections 
which allow transfer of relatively small molecules (up to a 
molecular weight of around 1000) e.g. cyclic nucleotides 
(Lowenstein, 1981). In addition the junctions have specific shape 
and charge characteristics. It would seem possible that some 
cytotoxic drugs, particularly the antimetabolites, could use gap 
junctions as a rapid mode of intercellular transport.
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THE APPLICATION OF GENERAL PHARMACOKINETIC PRINCIPLES OF ANALYSIS 
OF DRUG PENETRATION 
1.6
Advances in analytical techniques have allowed precise 
measurement of a wide range of cytotoxic drugs. Gel filtration, 
ultrafiltration and plasma dialysis allow determination of free 
drug, but usually whole plasma measurements are quoted. This, of 
course, gives only indirect evidence of the amount of drug at its 
site of action. It is possible, in certain cases to measure
simultaneous plasma and intratumoural drug concentrations and to 
relate these by pharmacokinetic models.
Measurement of tumoural drug levels is a means of assessing 
drug penetration in a quantitative way, however if the cytotoxic 
agent is compartmentalised within the tumour, drug content expressed
per total tumour weight would give an "average" value which would
fail to take account of intratumoral disposition. One further
drawback which limits the amount of information derived from 
measuring drug within solid tumours is the lack of a pharmacodynamic 
model which relates the tumoural pharmocokinetics to response. This 
field has recently been well reviewed by Powis (1985) but there are 
few clinical studies in which attempts are made to relate a drugs 
pharmacokinetic parameters to response.
A concentration - effect model has been designed and 
tested for adriamycin in nude mice bearing tumour xenografts 
(Chapter 11).
1.7 Volume of drug distribution
The volume of distribution (Vd) of a drug may be defined as a 
proportionality constant which relates the plasma concentration to 
the total amount of drug present in the body. This parameter has 
no direct physiological meaning but there are "ideal substances" 
which distribute into discrete compartments with physiological 
values. If a drug has extensive intracellular binding sites, then 
it will have a large Vd. The calcium channel blocker verapamil has 
been shown to enhance the cytotoxicity of adriamycin in vitro, 
probably by inhibiting active anthracycline efflux (Kaye and Merry, 
1985). We have recently demonstrated that co-administration of 
verapamil and adriamycin to patients with limited stage small cell 
lung cancer results in a significant pharmacokinetic interaction. 
There is an apparent increase in the peripheral compartmental Vd of 
adriamycin associated with administration of verapamil. Verapamil 
is a vasodilator and increases tumour blood flow by 50% in rats 
bearing a hind limb sarcoma (Kaelin et al, 1982). Alterations in 
intracellular binding or vasodilation with increased peripheral 
tissue adriamycin delivery could explain the altered Vd in this 
study.
1.8 Area under curve (ADC) / H
We have already defined the factors which control passive 
diffusion of drug molecules. All mathematical expressions 
describing diffusion have terms including the concentration
gradient, and duration of drug exposure. With regard to penetration 
by passive diffusion, it would seem most appropriate to relate this 
to the integral of concentration x time from zero to infinity (i.e. 
area under the curve of the plasma concentration time curve). This 
expression would relate total tumour drug exposure, and would 
therefore seem to be a better measure of drug penetration,
possibly, than peak plasma drug levels.
However, this may not hold for all drugs. Intracellular levels 
of adriamycin and daunomycin in leukaemic cells have been measured 
after rapid (10 minutes) or prolonged (24 hours) drug infusion 
(Peterson and Paul, 1983). Despite similarity in the plasma AUC's 
for rapid and prolonged infusions, the intracellular peak levels and 
AUC's were some 2-3 times higher after prolonged infusion. It would 
appear that for certain drugs, the temporal component assumes 
greater importance that the term denoting the concentration
gradient, in determining the degree of intracellular drug uptake by 
passive diffusion.
1.9 Tumour blood flow / 12
There has been some interest in the study of tumour blood flow 
and its potential manipulation using a variety of vasoactive drugs. 
Reports have been made of increased, normal or decreased sensitivity 
to vasoactive drugs on the tumour microvascular bed (Mattson and 
Peterson, 1981). The hypothesis underlying this work is that 
increasing tumour blood flow relative to normal tissue flow shouid 
provide enhanced delivery of chemotherapeutic drugs and perhaps 
increase tumour oxygenation. Organ clearance of a drug can be 
determined by a subtractive technique, if drug concentration 
measurements can be made in arterial and draining venous blood:
U = Q.Ca-Cv = Q.E
(U = organ clearance, Q =  blood flow, CA = arterial drug 
concentration, Cv = venous drug concentration, E = extraction 
ratio).
If the extraction ratio is low, the tumour drug clearance will 
be relatively unaffected by alterations in blood flow. However, if 
the extraction ratio is high, then clearance will be proportional to 
blood flow. There are little data concerning tumour drug extraction 
ratios, but if they are low, then manoeuvres to increase tumour 
blood flow would have relatively little therapeutic benefit.
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1.10 THE MULTI CELLULAR SPHEROID AS AN IN VITRO MODEL FOR STUDIES
ON DRUG PENETRATION 
The multicellular spheroid model was developed as a 
3-dimensional system of intermediate complexity between monolayer 
and solid tumours grown in vivo, which would simulate the growth 
properties, cellular kinetics and microenvironment of a micro­
metastasis prior to vascularisation. It is therefore possible to 
study drug penetration and distribution within solid tumours free 
from the constraints associated with host animal drug distribution 
and anomalies of tumour vasculature.
A number of techniques have been devised to study the 
penetration of drugs into spheroids. Conventional autoradiographic 
methods have been used successfully to demonstrate binding of 
methotrexate to dihydrofolate reductase in human osteosarcoma 
speroids. Using this technique, West et al (1980) demonstrated 
that methotrexate has limited ability to penetrate avascular tumour 
spheroids. They compared the degree of penetration of methotrexate 
to the growth fraction of the tumour, as measured by the tritiated 
thymidine labelling index, and found that the growth fraction was 
much greater than the fraction of cells reached by methotrexate.
Nederman et al (1981) have developed a "dry" method, which does 
not disturb the distribution of water soluble substances, based on 
freeze-drying and vapour fixation of spheroids prior to preparation
for autoradiography. They examined the penetration properties of a
3
number of low molecular weight substances such as H-D-Leucme 
o 3
H-thymidine and the cytotoxic drugs H-5-fluorouracil and 
3H-vinblastine. 5-fluorouracil distributes rapidly and evenly 
through human glioma spheroids whereas vinblastine is localised to 
the outer 3 - 4  cell layers.
Wibe (1982) has described the effects of vincristine on NHIK 
3025 spheroids, derived from a cell line originating from a human 
cervical carcinoma in situ. Following a series of sequential 
trypsinisation procedures and plating of cells from concentric 
spheroid layers, he showed that cells from the interior of the 
spheroid were relatively resistant to vincristine and that this 
could be explained in part by failure of vincristine penetration. A 
similar experimental approach was employed by Wilson et al (1981), 
in determining the cytotoxic activity of 4'(9-acridinyl amino) 
methanesulphon-m-anisidide (m-AMSA) in multicellular spheroids grown 
from Chinese hamster V79-171 cells. The resistance of spheroid 
cells to m-AMSA was a result of the slowly cycling state of the 
cells and drug transport limitations.
The original observation made on resistance to adriamycin in 
EMT-6 mammary tumour cell spheroids was made by Sutherland (1979). 
These workers determined the distribution of the natural 
fluorescence of adriamycin equivalents by direct florescent 
microscopy. A concentration gradient of fluorescence was observed 
from the outside to the centre of spheroids even after 
exposure to high drug concentrations (10/)ig/ml) for prolonged 
times (2 hours). Cells from enzymatically dissociated spheroids 
took up more drug than intact spheroids further indicating the 
existence of a significant diffusion barrier. By using a selective 
disaggregation technique after intact spheroids had been exposed to 
the drug it was possible to show directly that the inner spheroid 
cells were more resistant. The resistance was not due to differences 
in the cell cycle state of these inner cells therefore they 
concluded that in addition to drug penetration barriers, other 
factors related to the metabolic state of the cells and the 
microenvironment were implicated.
Similar studies have been performed which make use of the 
fluorescent properties of adriamycin. Durand (1981) used 
microfluorometric flow cytometry to determine the intracellular 
adriamycin content of disaggregated V79 spheroids. These studies 
confirmed the existence of a marked diffusion gradient for the drug. 
Intracellular fluorescence correlated well with cell survival from 
the various populations recovered from different spheroid layers. 
Durand (1982) has recently demonstrated that fluorescence activated 
cell sorting using the bisbenzamide stain, Hoechst 33342, can be 
used to separate cells as a function of depth within multicellular 
spheroids. The basis for the separation procedure is that the 
fluorescent DNA stain, as a result of its high avidity for cellular 
DNA, exhibits a marked diffusion/consumption gradient when it has to 
pass through several cell layers. Using a dual laser FACS 440, it 
proved possible to estimate intracellular levels of adriamycin and 
the ENA stain simultaneously, thus allowing correlation of cellular 
adriamycin content with "spheroid depth". The result of these 
elegant experiments are in agreement with the earlier work.
Erlichman and Vidgen (1984) examined the cytotoxic activity of 
adriamycin in the MGH-UI human bladder carcinoma line, grown as 
monolayer culture, as spheroids and xenografts in immune deprived 
mice. These studies suggested that adriamycin penetrates poorly 
into solid tissues, that in vitro clonogenic survival following 
adriamycin exposure of a cell suspension may predict falsely for 
drug sensitivity to chemotherapy and that the spheroid model more 
closely parallels the in vivo effects that does monolayer culture. 
This study was unusual in that dual cytotoxic end points for the
effect of adriamycin on the solid tumour grown subcutaneously were 
compared, namely growth delay and clonogenicity of the disaggregated 
tumour. These workers, and others, have shown that prolonged 
growth delay in response to adriamycin treatment is not necessarily 
associated with significant clonogenic cell kill. Growth delay is 
complex and depends on cell cycle time and the rate of cell loss, 
in addition to clonogenic cell kill. This study is therefore most 
useful as it allows comparison of monolayer, spheroid and xenograft 
survival directly, by means of clonogenicity. In an attempt to 
reveal that the spheroid model more closely parallels the in vivo 
effects than monolayer for adriamycin, the data presented by these 
authors has been ordered by introducing a term for "drug exposure". 
It is impossible to compare clonogenic survival in vitro and in vivo 
as the modes of drug exposure differ so widely. However, using a 
pharmacokinetic model developed to describe the pharmacokinetics of 
adriamycin in nude mice bearing human lung tumour xenografts (see 
Chapter 11) it is possible to derive a term for tumour drug exposure 
in vivo (by working out the cumulative area under the curve for 
adriamycin to which the tumour is likely to be exposed). It is also 
possible to convert the drug exposures in vitro to a cumulative AUC, 
and the result of their data, expressed in this way are summarised 
in fig 1.4. The clonogenic survival curve for spheroids, for an 
identical cumulative AUC is considerably closer to that seen for 
solid tumour than monolayer. Nevertheless, the clonogenic survival 
in spheroids is less than that for solid tumour indicating the 
intermediate complexity of the spheroid as a model for in vitro 
prediction of drug sensitivity.
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Several factors may be partly responsible for the dramatic 
increase in drug resistance of cells exposed in spheroids compared 
to exponentially growing cells in monolayer; differing drug 
metabolism in spheroid cells related to hypoxia; gradients in 
diffusion of nutrients to the spheroid core; protection of spheroid 
cells by intercellular communication; drug resistance of central 
hypoxic cells; differing cell kinetic parameters, with a 
predominance of slowly cycling and non-cycling cells in the centre 
of the spheroid; reduced drug availibility due to penetration 
barriers. It would seem unlikely that any single factor could 
explain spheroid cell resistance, rather a combination of factors 
which will vary for different drugs.
AIMS OF THESIS
The aims of this thesis are summarised as follows:-
a) Investigation of the cellular pharmacokinetics of adriamycin
accumulation in human lung tumour monolayers and its
relationship to cytotoxicity.
b) Comparison of the rate, degree of uptake and cellular
localisation of lipophilic derivatives of adriamycin in
monolayer systems
c) Conparison of adriamycin and lipophilic anthracycline
derivatives in multicellular spheroids with regard to 
differential penetration and cytotoxicity.
d) Identification of putative adriamycin penetration enhancing
agents, such as membrane permeabilisers, in monolayer and
their further study in spheroid culture systems.
/ 18
e) Investigation of the distibution and penetration of adriamycin
in solid tumour systems
f) Comparison of the pharmacokinetics and cytotoxicity of
adriamycin and adriamycin encapsulated in slow release 
surfactant vesicles (niosomes) in nude mice bearing human 
lung tumour xenografts.
/19
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CHAPTER 2
Cellular uptake and disposition of adriamycin and 4*-deoxy 
doxorubicin and its relationship to cytotoxicity in human non 
small cell lung cancer monolayers.
2.1. INTRODUCTION
4'Deoxydoxorubicin (4'-deoxy) is a new adriamycin analogue 
synthesised by removal of the hydroxyl group on the 41 position of 
the daunosamine sugar (Fig 5.2). The compound is less cardiotoxic 
than the parent drug and in a series of experimental tumours in 
the mouse, it showed antitumoral activity similar to and potency 
generally superior to that of adriamycin (Arcamone, 1977; 
Arlandini et al, 1977; Di Marco et al, 1977). Although the 
derivatised drug differs only in substitution of a single hydroxyl 
group, this confers notably different physico-chemical properties 
on the compound. 4'-deoxy is considerably more lipophilic than 
adriamycin and would therefore be expected to cross the lipid 
domain of the tumour cell membrane with greater facility. In this 
chapter, we report the relationship between intracellular levels of 
the two drugs and the corresponding cytotoxicity to human non­
small cell lung tumour cells in the exponential phase of 
monolayer growth.
2.2. Materials and Methods / 23
Cell culture: The L-DAN cell line was derived from our own
patient with squamous cell lung cancer. The cells were maintained 
as a monolayer in exponential growth on Ham's F-10/DMEM medium 
(50:50) with 8mM sodium bicarbonate supplemented with foetal calf 
serum. All experiments were carried out in the exponential phase 
of growth and the cloning efficiency of these cells ranged 
between 20-25%.
Conditions of drug exposure and determination of cell survival : 
L-DAN monolayers were exposed to a range of drug concentrations 
for differing times. The drugs were kindly supplied by Farmitalia 
Carlo Erba, and were administered to the cells in culture medium 
after dissolution in normal saline. After drug exposure, the 
cells were washed twice with ice cold phosphate buffered saline in 
order to remove loosely bound or surface absorbed drug. The cells 
were then harvested with 0.25% trypsin in PBS, centrifuged, washed 
once in ice cold medium and counted (Coulter Counter Ltd, Poole, 
England). The cells were then resuspended in distilled water and 
the resulting cell lysate was frozen and stored at -20 °C until 
drug extraction and analysis was performed.
During the clonogenic assay for cell survival, the monolayers 
were either exposed to the cytotoxic agents for one hour over a 
wide concentration range (O.lpg/ml to lOpg/ml) in growth medium or 
were exposed at a constant concentration of 5pg/ml for differing 
times (15-60 min). After drug exposure the cells were 
trypsinised, centrifuged and washed with ice cold medium. The 
cells were then diluted in medium and plated at 200 cells/ml into 
5cm diameter petri dishes. The plates were incubated for 12 days
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in a humid 2% CC^ atmosphere. The colonies were then fixed and 
stained with a solution of methylene blue (0.1%) in 70% ethanol 
and colonies of >40 cells were counted. Following the usual 
convention the cloning efficiency of the treated cells was 
expressed as a percentage of control survival.
Drug measurement: Intracellular levels of drug were measured by
extraction from the cell lysate with a mixture of chloroform and
isopropanol and subsequent analysis by high pressure liquid
chromatography (HPIC) utilising a fluorescent detector. This
method has been described in our laboratory (Cummings et al, 1984)
and allows detection of both parent drug and metabolites. All
solvents were of HPLC grade and the limit of detection of the
5
assay was 1 ng. Results were expressed as ng/10 cells.
Determination of oil-water partition coefficient: Lipid solubility 
was determined by measuring the partition of the drug between 
butanol and Tris-HCl buffer and expressing the result as the 
solvent/aqueous concentration ratio (Brodie, 1964).
Intracellular localisation of the drug: The cells were exposed in
monolayer to the drugs at a concentration of u^g/ml in medium for 
up to six hours. When the incubation had been completed the drug 
containing medium was removed and the cells washed with ice cold 
medium. A coversiip was mounted in uvinert and the cells examined 
under a Polyvar fluorescent microscope (Aexcitation = 486 nm;
\emission = 550 nm) using oil immersion (x400 magnification). In 
a separate experiment the cells were fixed with formol saline and
stained by Altmann's technique in order to demonstrate the 
cytoplasmic distribution of mitochondria. In addition, after 
exposure to both drugs (10 /ig/ml) for 2 hours, the cells were 
prepared routinely for electron microscopy, (sec 4.2)
Statistical analysis: Drug uptake curves were fitted using a
non-linear regressive technique on an in house programme based on 
the Marquhardt algorithm (Bevington, 1978).
2.3 Results / oc
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The effect of intracellular drug concentration and duration of
exposure on uptake by cells; The time course of uptake of 
adriamycin and 4'-deoxy figs 2.1 and 2.2) showed that the 
intra-cellular drug concentration was dependent on the drug 
concentration in the medium and the duration of drug-cell contact. 
Clearly 4'-deoxy (oil-water partition coefficient, 16.2) was taken 
up more rapidly and to a greater extent than the less lipophilic 
parent compound adriamycin (oil-water partition coefficient, 6.3). 
Using computer fitted data it was possible to calculate the initial 
rate of drug uptake.
The respective maximal rates of drug influx were Vimax,
5
Adriamycin = 0.156 ng/10 cell/min and Vimax, 4'-deoxy = 30
5
ng/10 cell/min. Fig 2.3 shows the relationship between 
intracellular and extracellular drug levels after exposure of one 
hour (the duration of cell-drug contact during the clonogenic 
assay).
Correlation between external and internal concentrations and cell 
survival; Based on extracellular drug concentrations, there is no 
significant difference in cell survival comparing adriamycin and 
4'-deoxy (Fig 2.4). The ID^ for adriamycin (2.1 /ug/ml) and 
4'-deoxy (2.2/ug/ml) are virtually identical, on the basis of medium 
concentration. However, if intracellular levels of drugs are 
plotted against cell survival (Fig 2.5), adriamycin achieves greater 
cell kill at relatively lower internal drug concentrations (LD^ q
5
adriamycin =3.5 ng/10 cells; intracellular LD^ 4'-deoxy =
72 ng/105 cells) .
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Relationship between cell survival and the duration of drug 
exposure: The greater the duration of drug exposure at constant
concentration, the greater the degree of cell kill (Fig 2.6). The 
relationship between cell survival and time was biexponential for 
4,-deoxy, with relatively greater cell kill after short drug 
exposures than adriamycin.
Intracellular drug metabolism: There was no evidence of drug
metabolism occuring in the medium. 4'-deoxy was metabolised 
within the cells to its alcohol, 4'-deoxydoxorubicinol (Fig 2.7).
The enzyme responsible for this (Bachur, 1979) is a ubiquitous 
cytoplasmic enzyme, NADPH-dependent aldo-keto reductase. The rate 
of alcohol formation was relatively constant over a wide range of 
external drug concentrations which may imply that the enzyme was 
not saturated despite the relatively high intracellular drug 
concentrations achieved. We were unable to detect adriamycinol in 
the adriamycin treated cells. It is possible that the alcohol is 
being formed but is below the limit of detection in our HPLC assay 
as the intracellular levels of the parent drug is low.
Intracellular localisation of drug: The monolayers were examined 
sequentially for 6 hours after exposure to both drugs at fixed 
concentration (5^ ug/ml). Intracellular adriamycin was confined to 
the nucleus as far as could be determined by light microscopy (fig 
2.8). 4'-deoxy was localised solely within the nucleus with 
incubations for 10 minutes but granular cytoplasmic fluorescence 
had appeared by 20 minutes and thereafter increased in degree 
until it predominated (fig 2.9). We considered the possibility 
that 4'-deoxy was binding to mitochondria within the cytoplasm,
however, Altman's mitochondrial stain demonstrated a different 
size and distribution of granules from these "stained" by 
4'-deoxy. Ultrastructural studies (Fig 2.10) showed marked 
nuclear disruption and chromatolysis after treatment with both 
drugs. However, large lysosomal vesicles were seen in the cells 
treated with 4'-deoxy.
2.4 DISCUSSION
We have demonstrated that deletion of a hydroxyl group on 
the daunosamine moiety profoundly alters the physico-chemical 
properties of adriamycin, particularly lipid solubility. The 
increased lipophilicity of 4'-deoxy as manifested by the elevated 
oil-water partition coefficient, is probably the main factor 
contributing to the increased rate and cellular uptake seen with 
this drug in our monolayer systems. Cassaza (1979) has reviewed 
the relationship between cell uptake in vitro and the partition 
coefficient of anthracycline analogues, and for groups of 
homogeneous derivatives it would seem that lipid solubility is an 
important determinant of cell uptake. Di Marco et al (1977) have 
compared cell uptake of the two drugs over a limited concentration 
-time range in a suspension of L1210 cells. They expressed 
intracellular drug levels as the ratio of moles drug bound/mole 
DNA and found a 14-times greater accumulation of 4'-deoxy in that 
cell system.
Biological membranes are lipoid in nature and the ease with 
which a drug molecule will cross a membrane will depend, in part, 
on its ability to dissolve in the lipid domain of the cell 
membrane. Skovsgaard (1978) demonstrated that membrane transport 
is rate limiting for adriamycin uptake in Ehrlich ascites tumour 
cells and he proposed a carrier mediated drug transport mechanism. 
However, more recently, Dalmark (Dalmark, 1981; Dalmark and Storm, 
1981; Dalmark, 1982) has presented transport data from human 
erythrocytes and Ehrlich ascites tumour cells, from which it 
appears that adriamcyin transport takes place by free diffusion of 
the electroneutral molecule through the lipid domain of the cell 
membrane. Adriamycin can self-associate through hydrophobic 
interaction in aqueous solution and form dimers to which the cell
is relatively impermeant. This situation would mimic a carrier 
mediated transport process although transport of the permeant 
takes place by simple Fickian diffusion. This may be the 
explanation for the earlier finding of Skovsgaard. Our results 
would tend to support Dalmark's hypothesis in that the more lipid 
soluble drug is accumulated to a greater degree.
On the basis of extracellular drug concentrations, cell kill 
was virtually identical for both adriamycin and 4'-deoxy. 
However, the correlation between intracellular drug concentrations 
and cytotoxicity differed for adriamcyin and 4'-deoxy. For a 
given intracellular concentration, adriamycin is more cytotoxic 
than 4'-deoxy. The log cell survival plot (Fig 2.5) for 
adriamycin is linear over the intracellular concentration range 
whereas the curve for 4'-deoxy is biphasic with a relative plateau 
after 1% cell survival
The relationship between cell survival and the duration of 
drug exposure is mono-exponential for adriamycin and biexponential 
for 4'-deoxy. There is relatively greater cell kill during short 
drug exposure for 4'-deoxy, which is probably related to the rapid 
rate of cell uptake. It is interesting to note that the curves 
for cell survival vs. intracellular drug concentration, and cell 
survival vs. duration of drug exposure are both biphasic. It is 
possible that the initial rapid phase of drug uptake is the major 
determinant of cytotoxicity.
These results are similar to those reported by Bhuyan et al 
(1981) who studied intracellular uptake of another lipophilic 
anthracycline, 7-con-0-methylnogarol (7-OMEN) in Chinese hamster 
ovary, B16 and L1210 cells in culture. 7-OMEN was taken up more
rapidly in B16 cells than adriamycin and had a biphasic cell 
survival curve. The biphasic curve may implicate a resistant 
subpopulation or, perhaps more likely as Bhuyan commented, may be 
a characteristic of a drug which showed predominant accumulation 
in the cytoplasm.
The time course of drug distribution within the cell is 
conspicuously different, as demonstrated by fluorescent 
microscopy. Adriamycin was located mainly within the nucleus 
whereas 4'-deoxy was distributed both in the nucleus and in a 
granular fashion within the cytoplasm. Initially we considered 
the possibility that 4'-deoxy was binding to mitochondrial 
structures but conventional histochemical localisation of 
mitochondria using Altmann's stain showed an entirely different 
distribution. Facchinetti et al (1978) studied the time 
course of intracellular distribution of adriamycin and 
N-trifluoroacetyladriamycin-14-valerate (NTAV) in mouse peritoneal 
macrophages. They found that adriamycin cytofluorescence, at 
higher extracellular concentrations than used in our experiments, 
was seen initially in the nucleus and later appeared in a granular 
distribution within the cytoplasm. The lipophilic derivative NTAV 
localised within the cytoplasm in a granular fashion with a 
similar destribution to 4'-deoxy. Ultrastructural studies showed 
that NTAV was bound within intracytoplasmic vesicles of an 
amorphous nature. Electron microscopy following cellular exposure 
to 4'-deoxy revealed large lysosomal vesicles, which could have 
been the fluorescent granular structures seen on light microscopy 
in this present study.
It would only require approximately 2-5% of total
intracellular 4’-deoxy to bind to the nucleus to give levels 
approximate to total intracellular adriamcyin (for a given
concentration/time exposure). Fluorescent microscopy is a rather 
insensitive method of quantitating the amount of drug present 
within specific cell structures but it is possible that nuclear
binding of 4'-deoxy is occuring to a significant extent although
■ fluorescent light microscopy- reveals a predominantly cytoplasmic 
distribution. Egorin et al (1980) have shown that DNA can quench 
the fluorescence of some anthracyclines more than that of others, 
which may be a further contributing factor.
These results indicate that the relationship between 
cytotoxicity and intracellular drug levels is complex when 
comparing a lipophilic deriative with its parent compound. The 
importance of anthracyclic cytofluorescence distribution is 
unknown. Egorin et al (1980) have examined the intracellular 
localisation of a number of different anthracyclines and have 
shown that there is no correlation between the intracellular 
distribution of drug after exposure to intact cells and 
accumulation by isolated nuclei . It is possible that 
differential nuclear-cytoplasmic localisation may not be related 
to different modes of drug action at cellular level but may 
represent intracytoplasmic storage for lipophilic drugs. 
As a result of these findings in monolayer, these drugs were then 
compared in a multicellular spheroid model.
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Figure 2.1 Intracellular levels of adriamycin following exposure to a range 
of external drug concentrations for up to 3 hours. Each point 
represents the mean of 4 experiments and the vertical bar denotes 
1 stand deviation.
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Figure 2.2 Intracellular levels of 4'-deoxy following exposure to a range of
external drug concentrations for up to 2 hours. Each point represents 
the mean of 4 experiments and the vertical bar denotes 1 standard 
deviation.
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Figure 2.3 The relationship between intracellular and extracellular drug 
concentrations for adriamycin (ft ) and 4'-deoxy (O ). Each 
point is the mean of 4 experiments and the vertical bar denotes 
1 standard deviation.
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2  4 -  DEOXYDOXORUBICIN (+SD)
Figure 2.
-----  ,--- ----- ,-------— ,-------- ,---------j
0 2  4  6  8  10
External Drug Cone. (j4g/ml)
4 Clonogenic survival for LDAN monolayers exposed to adriamycin (• ) 
or 4'-deoxy (o )• Each point represents the mean of 4 experiments 
and the vertical bar denotes 1 standard deviation.
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Figure 2.6 The relationship between clonogenic cell survival and the
duration of exposure at constant drug concentration, 5 ug/ml. 
(Adriamycin, • ; 4'-deoxy O ). The curves were computer 
fitted to data from 2 experiments.
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Figure 2.7 Intracellular levels of 4'-deoxydoxorubicinol after exposure 
to a range of concentrations of 4*-deoxy. Each point is the 
mean of 4 experiments and the vertical bar denotes 1 standard 
deviation.
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Figure 2.8 Fluorescent photomicrograph of L-DAN monolayers 
treated with adriamycin (2 ?ug/ml for 2 hours). 
Nuclear staining is evident (magnification x 150).
Figure 2.9 Fluorescent photomicrograph of L-DAN monolayers
treated with 4'-deoxy (2 pg/ml for 2 hours). There 
is granular, cytoplasmic fluorescence in addition 
to nuclear and nuclear envelope staining 
(magnification x 150).
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Figure 2.10 Electron micrograph of L-DAN cell. A) Normal Cell 
B) Cell treated with 4- '-deoxy. Note nuclear 
disruption and chromatolysis and cytoplasmic lysosomal 
vesicles (arrowed) (magnification x 2950)
CHAPTER 3
Penetration and relative cytotoxicity of adrianycin and 4'-deoxy- 
doxorubicin in human lung tumour spheroids.
3.1 INTRODOCTICN
The multicellular spheroid model was developed as a system of 
intermediate complexity between solid tumours and monolayers in 
which 3-dimensional growth of cells creates microenvironments that 
simulate micrometastatic foci (Sutherland et al, 1981). Resistance 
of intact spheroid cells to drug treatment has been reported for a 
number of cytotoxic agents and the existence of drug penetration 
barriers has been postulated (Nederman et al, 1981)
Fluorescent microscopic (Sutherland et al, 1979) and flow 
cytometric (Durand, 1981) studies have shown that adriamycin is 
localised within the outer cell layers of V79 Chinese Hamster 
spheroids and that the inner spheroid core cells are relatively 
resistant to the cytotoxic effects of the drug. We have shown that 
4*-deoxydoxorubicin (4'-deoxy), a lipophilic derivative of 
adriamycin is taken up more rapidly and to a greater extent than 
the parent drug by human lung tumour cells grown as monolayers, 
although its cytotoxic activity in this system is similar to that 
of adriamycin. In this study we have assessed differential 
penetration of the two drugs in human lung tumour spheroids by 
Fluorescent microscopy and have compared their cytocidal effects in 
spheroid and monolayer.
3.2 MATERIALS AND METHODS / 43
Cell Culture: The L-DAN cell line was derived from our own patient
with squamous lung cancer. The cells were maintained as a monolayer 
in exponential growth in Ham's F10/DMEM (50:50) with 8irM NaHCO^ 
supplemented with foetal calf serum. The monolayers were 
disaggregated enzymatically with 0.25% trypsin in PBS and the 
resultant cell suspension used to provide cells for initiation of 
tumour spheroids, using the "agar underlay" static method (Yuhas et 
al, 1977).
During growth delay experiments, spheroid size was monitored by 
twice weekly measurement of cross-sectional areas of individual 
spheroids using a "Micromeaurements" image analysis system coupled 
via a television camera to an inverted optical microscope 
(Twentyman, 1982). These area measurements were subsequently 
converted to volumes, assuming spherical geometry.
Conditions of drug exposure and determination of cell survival:
L-DAN monolayers and spheroids were exposed to both drugs over a
range of concentrations 0.1 - 20 jig/ml) for 1 hour, or at a fixed
drug concentration of 10 yig/ml for varing periods of time (15 
minutes - 2 hours). The monolayers were treated in both the 
exponential and plateau phase of growth. Exponentially growing
cells were harvested on day 3, plateau phase cells on day 7. The 
drugs were kindly supplied by Farmitalia Carlo Erba and were 
administered to the cells in culture medium after dissolution in 
normal saline.
After treatment, the monolayer cells were harvested with 0.25% 
trypsin in .PBS, centrifuged and washed with ice cold medium.
The cells were then diluted in medium and seeded at 200 cells/ml in 
5 cm petri dishes. The plates were incubated for 12 days in a 
humid 2% CC^ atmosphere. The colonies were then fixed and 
stained with methylene blue and colonies of >40 cells were counted. 
Following the usual convention the cloning efficiency of the 
untreated cells was normalised to 100% and the cloning efficiency 
of the treated cells was expressed as a percentage of control 
survival.
Spheroids from two flasks were pooled and a number of glass 
universal tubes were prepared, each containing two to three 
hundred spheroids with a mean diameter of approximately 35tyam. The 
spheroids were treated with similar drug concentrations and 
durations of exposure as used in monolayer at 37 °C with 
intermittent agitation. At the end of this period the spheroids 
were allowed to sediment, the drug containing medium was removed 
and they were washed with fresh, ice cold medium. The spheroids 
were then resuspended in medium and subdivided for assays of 
response, (figure 3.1)
Approximately half of the spheroids were incubated with 0.125% 
trypsin in PBS for 15 minutes at 37 °C, after which the trypsin 
was removed and replaced with fresh medium. The spheroids were 
then mechanically disaggregated to a single cell suspension by 
repeated pipetting. The clonogenic assay was repeated as 
previously described.
A pasteur pipette was used to transfer spheroids from the 
other group to agar coated wells on a plastic tissue culture 
multidish with 1 spheroid per well. Twenty four spheroids were 
taken from each treatment group, and area measurements were made
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twice weekly as described. It was possible therefore to measure 
treatment induced growth delay, which was defined as the time taken 
for median spheroid volumes to increase by a factor of ten above 
initial size.
Determination of intracellular drug levels: The pH of adriamycin
containing culture medium (5 jjg/ml) was adjusted to give a range 
from pH 5.5 - 8.5 (pH meter; Inio Electronics Ltd). The monolayers 
were exposed for 30 minutes to the drug containing culture medium, 
and incubated at 37 °C. The cells were then washed twice with
ice cold PBS and harvested by a brief exposure to trypsin and 
counted by a Coulter Counter. Adriamycin was extracted from the 
resulting cell suspension by vortexing with organic solvents 
(Chloroform and isopropanol) and measured by an HPLC technique with 
fluorescence detection, previously described by our laboratory
5
(Cumming et al, 1984). Extracted drug was expressed as ng/10 . 
cells.
Fluorescent microscopy; Intact spheroids approximately 500 um in 
diameter were exposed to adriamycin and 4!-deoxy for varying times 
(30 mins to 4 hours) with a medium concentration of 5 pg/ml. The 
spheroids were then washed to remove loosely bound drug, placed in 
gelatin capsules filled with OCT embedding gel (Lurker Labs Ltd) 
and frozen in liquid nitrogen. Thin sections (6 jm) were 
subsequently cut using a cryotome, mounted in uvinert and examined 
under a Polyvar fluorescent microscope ( \ excitation = 486;
^ emission = 550 nm).
3.3. RESULTS
Effect of pH on adriamycin uptake in monolayer: Intracellular
adriamycin levels have been plotted against extracellular pH 
(Fig 3.2 a + b). The curve was fitted by non-linear least squares 
and is sigmoidal in shape. There is a 7.5-fold difference in 
intracellular drug levels from pH 5.5 to pH 8.5. Fifty per cent of 
total drug uptake occurred at approximately pH 7.5.
Cell survival in spheroids and monolayers; Each experiment was 
repeated at least 4 times, but for the sake of clarity the results 
of 2 experiments are shown in each figure. All the curves were 
computer fitted to the data shown.
Based on extracellular drug concentrations, there is no 
significant difference in clonogenic cell survival after treatment 
of monolayers in the exponential or plateau phase of growth with 
the two drugs (Fig 3.3). On the basis of external drug 
concentration, plateau phase cells are considerably more resistant 
to both drugs than exponentially growing cells. The respective 
exponential ID^'s for adriamycin and 4'-deoxy are 2.Jug/ml and 
2.^ ug/ml and the plateau phase ID^ q 's are 3.?ug/ml and 3.5ug/ml. 
Typical spheroid growth delay data after treatment with a range of 
adriamycin concentrations are shown in Fig 3.4. The control curve 
follows Gompertzian kinetics and the treated spheroids regrow at a 
rate parallel to control. It is apparent that 4'-deoxy induces 
relatively larger delays in growth for equivalent drug 
concentrations (Table 3.1, Fig 3.5). Clonogenic cell survival 
after disaggregation of treated spheroids was significantly higher
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for a given dose than for monolayer, and differed for the two drugs 
(Fig 3.6). Adoption of spheroid configuration confers a degree of
resistance to drug treatment, relative to monolayer, which is
partially overcome by 4'-deoxy.
The longer the duration of exposure of the monolayers to
adriamycin, the greater the clonogenic cell kill. There is an
apparent log linear relationship between the duration of adriamycin 
exposure in monolayer and clonogenic cell kill at fixed drug 
concentrations (Fig 3.7). Clonogenic cell survival after 
disaggregation of intact spheroids decreased with increasing 
duration of exposure but was higher than for monolayer and the 
spheroid cell survival curve is biexponential.
Spheroid growth delay, as a function of drug exposure time, 
is summarised in Table 3.2. It is apparent that a plateau phase is 
achieved with no further significant increases in growth delay with 
drug exposures of greater than 90 minutes (Fig 3.8)
Fluorescent microscopy; It was possible to evaluate the degree of 
penetration qualitatively using fluorescence microscopy. Sections 
stained with haematoxylin and eosin showed that there are 
approximately 10-12 cell layers from the outer layer to the centre 
in spheroids approximately 300-400pm in diameter, with a necrotic 
centre (Fig 3.9). After drug exposure, (5 pg/ml for 2 hours) 
adriamycin was seen in the nuclei of the outer 3-4 cells, (Fig 
3.10) whereas 4'-deoxy had penetrated further to a depth of 6-7 
cell layers (Fig 3.11). Prolongation of drug exposure times did 
not appear to significantly enhance further drug penetration.
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3.4 DISCUSSION
We have shown that the 3-dimensional structure of the spheroid 
confers a degree of resistance to the anthracyclines adriamycin and 
4'-deoxydoxorubicin, relative to the monolayer. A number of 
factors have been considered relevant to cytotoxic drug resistance 
in spheroids, including - intrinsic cellular drug resistance; 
failure of drug penetration; alteration in cell cycle kinetics; 
microenvironmental changes within the spheroid which could affect 
the physicochemical properties of the drug; protection of spheroid 
cells by intercellular communication; drug resistance of central 
hypoxic cells (Wibe, 1980). One would expect that the phenomenon 
of drug resistance in cells grown as spheroids is likely to be a 
combination of these factors. We have compared identical cells in 
monolayer and spheroid, therefore the difference in spheroid 
sensitivity is unlikely to be due to intrinsic drug resistance.
The cell cycle distribution is not identical when comparing 
cells grown as spheroids and monolayer. Actively cycling cells 
tend to predominate on the exterior layers of the spheroid, whereas 
plateau phase cells tend to make up the majority of internal cells. 
Chambers et al (1984) have shown that there is a complex 
relationship between intracellular adriamycin levels and the 
proliferative state of EMT6 cells. For a given intracellular 
concentration of drug, plateau phase cells were found to be 
relatively more resistant than exponentially growing cells. We 
have shown that human lung tumour plateau phase cells are 
significantly more resistant to adriamycin and 4'-deoxy but to a 
similar degree (Fig 3.3).
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It is possible that the degree of resistance conferred by 
adoption of spheroid configuration could be explained, at least in 
part, by the unfavourable proliferative state of spheroid cells. 
Nevertheless, despite both drugs having identical effects on 
monolayer cells in both phases of growth, 4'-deoxy is significantly 
more toxic to multicellular spheroids. Kwok and Twentyman have 
compared the response to adriamycin of EMT6 cells, treated as 
intact or diasaggregated spheroids. In that study, the cell cycle 
distribution of the two cell populations was identical, and yet it 
was apparent that the sensitivity of disaggregated spheroid cells 
was greater than that of intact spheroids.
The duration of drug exposure is an important determinant of 
survival. There is a linear relationship between the two for 
monolayer, at least over the times used in these experiments. 
However, the clonogenic cell survival curve was biphasic, for 
disaggregated spheroid cells, with a lesser degree of cell kill.
This plateau effect is also seen when spheroid growth delay is 
plotted against time (Fig 3.8) with no further apparent increase in 
growth delay with drug exposures of greater than 90 minutes. 
Fluorescent microscopy shows that even after prolonged exposure to 
adriamycin (up to 4 hours) the drug does not reach the centre of 
the spheroid. This may explain the disparity in shape between the 
monolayer and disaggregated spheroid cell survival curves.
Adriamycin is a basic drug (pK 8) and the amino group of the 
daunosamine sugar moiety is likely to be protonated at acidic pH 
(the amount of ionised drug can be derived from the Henderson- 
Hasselbach equation) (Fig 3.2b)
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We have shown the dependence of cellular drug uptake on 
external pH, in monolayer (Fig 3.2a). Using microelectrodes, Acker 
et al (1982) have demonstrated significant gradients in oxygen, pH 
and glucose from the external to internal spheroid cell layers. 
There is some histological evidence on central necrosis in spheroids 
of approximately 400 ^ jm in diameter, which would be likely to be 
associated with a relatively acidic pH. This pH gradient may 
therefore influence adriamycin ionisation and hence be a 
contributory factor to the failure of the drug to penetrate to the 
centre of the spheroid core. This is consistent with the concept 
that adriamycin enters the cell by diffusion of the electroneutral 
molecule through the lipid domain of the cell membrane.
Both adriamycin and 4*-deoxy cause significant growth delays 
(Table 3.1) without a very marked degree of clonogenic cell kill 
(Fig 3.6). For example, 4*-deoxy induces spheroid growth delay of 
approximately 25 days following exposure to 10 jig/ml for 1 hour, 
whereas an identical drug exposure yields only 60% clonogenic cell 
kill.
Figure 3.4 shows a series of growth and regrowth curves for 
L-DAN spheroids folowing treatment with adriamycin. Untreated 
spheroids grow exponentially, with a doubling time of approximately 
3 days until a diameter of about 700-800 jm was reached, after which 
growth slowed in a Gompertzian retardation phase. Treated 
spheroids exhibited either a static phase, or a regression phase 
(depending on dose) which was followed by a recovery of the growth 
curve to a pattern similar to that for untreated spheroids. The 
exponential portions of these regrowth curves were, to a reasonable 
approximation parallel to each other and to the corresponding
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portion of the control growth curve. Clonogenic survival curves 
may, in principle, be deduced from such data by back-extrapolation 
of regrowth curves to zero dose.
Such deductions have previously been attempted as a means of
obtaining 'in situ' survival curves for experimental tumour
irradiated in vivo but, in that situation, the analysis is
complicated by the existence of the tumour bed effect, the limited
proliferation potential of 'doomed cells* and the difficulty of
obtaining accurate measurements of the regrowing tumour over an
adequate range of sizes (Wheldon, 1980). For spheroids, the
problem is simpler in that the tumour bed effect is necessarily
absent in vitro, observations over a wide range of sizes are
feasible and (at least for the present spheroid line) doomed cell
proliferation evidently does not substantially influence regrowth.
The effect of mitotic delay would be negligible at these doses. It
seems reasonable to interpret these spheroid response data as being
consistent with the instantaneous reduction by cytotoxic drug
treatment of clonogenic cell number in each spheroid from ^
(immediately before treatment) to N ^  immediately after the
treatment (with the surviving cells immediately resuming
(+)exponential growth). The quantity Nq v will be proportional 
to the Y-intercept (at zero dose) of the extrapolated exponential 
portion of the regrowth curve i.e. it is proportional to the volume 
from which the spheroids 'apparently' regrew. The clonogenic 
surviving fraction following treatment (S) is then simply the ratio 
Nq ^  to Nq ^ . By repetition of this estimation procedure 
at each dose level for which regrowth curves are available a dose- 
dependent survival curve may be estimated for the cells of the 
spheroid.
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The surviving fraction was calculated, but the clonogenic cell 
survival predicted by the growth delay data was considerably lower 
than that found by actually cloning disaggregated spheroids. At the 
highest drug concentrations used, the difference between the 
predicted and actual clonogenic survival differed by 100 fold.
There are a number of other factors which can contribute to 
growth delay apart from clonogenic cell kill. Steel (1977) has 
proposed the folowing formula for changes in tumour cell-cycle 
kinetics.
Td = _______log 2 ____
Tc (1-0) log (GF + 1)
Tc = length of tumour cell cycle, GF = growth fraction 
0 = rate of cell loss Td = tumour volume doubling time.
It is possible that the anthracyclic compounds cause prolonged 
growth delays in a number of ways; incurring a cell-cycle delay; 
reduction in the growth fraction of the tumour; an increased rate of 
cell loss. Growth delay is therefore a complex end point in 
assessing the relative potency of cytotoxic drugs but is presumably 
valid if members of the same generic class of compounds are 
compared.
4'-deoxy induced a longer growth delay and greater clonogenic 
cell kill than adriamycin. There is no difference in the cell 
cycle specificity of the two drugs, but we have demonstrated that 
the lipophilic analogue partitions into the spheroid more rapidly, 
and to a greater degree. It is tempting to speculate that
adriamycin penetration is a relatively important aspect of spheroid 
drug resistance in our model system, and that we have partially 
overcome this by using a lipophilic analogue. The 3-dimensional 
spheroid model may be an important additional method by which new 
lipophilic analogues of existing cytotoxic drugs should be assessed 
preclinically, as part of the selection procedure for further 
development.
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MEDIAN GROWTH 95% CONFIDENCE
DELAY (days)* LIMITS **
ADRIAMYCIN
0 8.1 6.3-8.9
1 11.5 10.0-14.2
5 13.1 12.0-14.9
10 17.3 15.4-18.3
12.5 16.4 15.3-17.9
20 17.4 14.5-19.2
41-DEOXY
0(control) 6.4 5.0-6.8
1 15.9 13.0-18.5
5 19.4 15.4-20.5
10 24.9 NA***
15 29.5 NA
* The growth delay was taken to be time to reach x 10 original 
volume.
** Approximate 95% condifence limits on medium spheroid volumes 
were calculated by the method of Nair (cited by Colquhoun, 1971). 
Growth curves were constructed for each experimental group using 
upper and lower limits on median volume. Growth delay values were 
obtained from each of these curves and are referred to as 95% 
confidence limits on median spheroid growth delay.
*** NA - not assessable (upper bound required extrapolation beyond 
available data).
TABLE 3.1 - Growth delay of L-DAN spheroids exposed to different 
concentrations of adriamycin or 4'-deoxy for a fixed time (one 
hour).
CONCENTRATION
j^g/ml)
ADRIAMYCIN MEDIAN GROWTH* 95% CONFIDENCE
EXPOSURE TIME DELAY (days) LIMITS**
(rain) (days)
0 8.5 7.0-10.2
15 10.6 9.0-12.0
30 13.0 11.3-14.5
60 20.4 19.0-26.5
90 27.5 22.2-30.2
120 27.5 19.5-30.0
* The growth delay was taken to be time to reach x 5 original 
spheroid volume.
** Approximate 95% confidence limits on medium spheroid volumes 
were calculated by the method of Nair (cited by Colquhoun, 1971). 
Growth curves were constructed for each experimental group using 
upper and lower limits on median volume. Growth delay values were 
obtained from each of these curves and are referred to as 95% 
confidence limits on median spheroid growth delay.
TABLE 3.2 - Growth delay of L-DAN spheroids exposed to a fixed 
concentration of adriamycin (KJug/ml) for different lengths of
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Figure 32a The .relationship between intracellular adriamycin levels and
extracellular pH. Each point is the mean of 5 experiments and 
the vertical bars denote 1 standard deviation.
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Figure 3,2b The effect of pH on the ionisation of a weak acid. The acid is 
50% ionised at a pH = pka. At higher pH values it becomes 
increasingly more ionised. A mirror image could be constructed 
for a weak base. .
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(O i •) or 4'-deoxy ( A ( A). Each point is the mean of 4 
experiments and the vertical bars represent 1 standard deviation.
Lo
g 
V
O
L
U
M
E
/59
CN
CN
;X X
00
o p  t e c  *
00o
I
o
■pcoo
c e
CO
<DLi3
GO
•H
[*4
/60
r
REGROWTH DELAY ( x 10)
20H
12 H
$
4H
5 10 15 20
DRUG CONC.(pg/ml)
Figure 3.5 Dependence of regrowth delay on drug concentration, with fixed 
duration of exposure
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Figure 3.6 Clonogenic cell survival of monolayers (A  ,0 ) and disaggregated 
spheroids (^,6) following exposure to adriamycin (O ,• ) or 
4'-deoxy JU). The curves are computer fitted to the mean of
2 experiments.
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Figure 3.7 The relationship between clonogenic cell survival and the duration of 
adriamycin exposure at fixed concentration ( 10 ygfml)
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Figure 3.8 The dependence of spheroid growth delay on the duration of 
exposure to adriamycin at fixed concentration (10 ug/ml).
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Figure 3.9. Section through an L-DAN spheroid stained with 
haematoxylin and eosin (magnification x 100)
Figure 3.10. External surface of and L-DAN spheroid exposed to 
adriamycin. The outer 3 - 4  cell layers are most 
highly labelled with drug and there is a clear 
diffusion gradient within the spheroid (magnification 
x 100).
Figure 3.11 External surface of an L-DAN spheroid exposed to 
4'-deoxy. The drug has diffused further into the 
spheroid and the external cells are more highly 
labelled compared to adriamycin (magnification x
CHAPTER 4
Intxatumoural distribution and pharmacokinetics of adriamycin 
and 41 -deoxydoxorubicin in rats bearing a methyl cholanthrene 
induced sarcoma.
4.1 INTRDDOCTION
Thus far, the comparative subcellular localisation and spheroid 
diffusion gradients of adriamycin and 4'-deoxy have been described. 
One would predict, from the work of Goldacre and Sylven, that the 
distribution of these cytotoxic drugs would not be homogenous within 
solid tumours, given the apparent penetration barriers facing 
anthracyclines in tumour spheroids a few hundred microns in 
diameter.
Ozols et al (1981) examined the penetration of adriamycin into 
murine ovarian cancer cells grown intraperitoneally in C3HeB/FeJ 
mice. Adriamycin-specific intranuclear fluorescence was detected in 
the ascites cells soon after an intraperitoneal dose, but was 
undetectable at any time following an equitoxic intravenous dose. 
Interestingly, adriamycin given intraperitoneally penetrated only 
into the outermost 4 to 6 cell layers of the solid intra-abdominal 
tumour nodules whereas after the intravenous route adriamycin - 
specific fluorescence was observed in a patchy distribution 
throughout the tumour. The authors concluded that intraperitoneal 
administration of adriamycin has both pharmacokinetic and tissue 
penetration advantages over the standard intravenous route for
I
ovarian tumour confined to the abdominal cavity.
Durand has recently introduced a method for separating tumour 
cells as a function of their distance from the blood supply. The
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basis for this separation procedure is that the fluorescent 
bisbenzamide stain, Hoechst 33342, as a result of its high avidity 
for cellular DNA, exhibits a marked diffusion/consumption gradient 
when it has to pass through several cell layers. This results in a 
situation where the cells closest to the drug "resevoir" i.e. media 
in the case of multicell spheroids or blood supply in the case of 
solid tumours in vivo, become more intensely stained. Preliminary 
results from that laboratory following treatment of Lewis lung 
carcinoma bearing mice with adriamycin or external beam radiotherapy 
indicate that tumour cell survival can be related to the 
intensity of dye staining (the most intensely labelled cells, 
which are therefore closest to the blood supply, are most sensitive 
to X-rays or adriamycin).
In this chapter, the intratumoural distribution* pharmaco­
kinetics and antitumour activity of adriamycin and 4'-deoxy has been 
examined in tumour bearing (MC40A) rats utilising fluorescence 
microscopy. In addition the relative cardiac toxicity of the two 
compounds has been assessed by electron microscopy.
4.2 Materials and Methods / 68
Drug administration For the drug distribution studies, adriamycin 
(40 mg/Kg) and 4'-deoxy (20 mg/kg) were administered in equitoxic 
doses by continuous intravenous infusion over a period of 2 hours 
(Vickers Automatic Pump, Vickers Engineering, England). Both drugs 
were reconstituted in normal saline immediately prior to use. The 
rats were anaesthetised using a nose cone connected to a Flutec 3 
anaesthetic machine which delivered 2% Halothane in nitrous oxide 
for the duration of the infusion. A fine polyethylene cannula was 
inserted into the left carotid artery and was heparinised and 
connected by a Luer lock to the Vickers pump.
MC40A Tumour This tumour is a methyl cholanthrene induced
fibrosarcoma. The tumour was passaged surgically in approximately 
100 mg fragments, and implanted, under light ether anaesthesia, in 
the recipient Wistar rat's (inbred community) flank. When the
tumours were approximately 1.5 cm in diameter, tumour growth delay 
experiments were instituted. Three groups of 10 animals were 
treated with 10 mg/Kg intravenously of adriamycin or 4'-deoxy and 
normal saline as control. Tumour volumes were measured by
bidemensional estimation of tumour diameter using special calipers. 
These estimates of tumour volume were made 3 times weekly for 14
days.
Tissue preparation for fluorescent studies At the end of the drug 
infusion, the rats were sacrificed by exsanguination. Heart, liver, 
one kidney, a portion of skeletal muscle from the gastrocnemius 
and the tumour were excised, washed in ice cold saline and blotted
/69
dry. The tissues were then immersed in liquid nitrogen and stored 
frozen at -70°C. 6 pm sections were then cut on a cryostat and
mounted in uvinert.
The slides were examined for adriamycin specific fluoresence 
using a Polyvar fluorescent microscope ( ^  excitation = 468 nm; 
^ emission = 550 nm) .
Tissue preparation for drug levels - Tumour bearing Wistar rats were 
treated 7 days after tumour transplantation. Adriamycin or 4'-deoxy 
was administered by intravenous bolus at idential doses of 10 mg/kg. 
Following drug administration two animals from each group were 
sacrificed by cervical dislocation (0, 15 minutes, 30 minutes, 1 
hour, 2 hours, 4 hours, 8 hours, 12 hours and 24 hours). A blood 
sample was collected from the inferior vena cava, and the heart and 
tumour excised and washed free of blood with normal saline. The 
blood sample was centrifuged at 2000 rpm for 5 minutes and the 
plasma separated and stored at -70°C with the tissue samples until 
analysed.
Drug assay Prior to extraction, plasma and tissues were allowed 
to thaw at room temperature. One to two grams of heart and tumour 
were suspended in 3 vol of buffered normal saline - and finely 
minced with an Ultra Turnes electrically driven rotating cutting 
blade for 30 seconds. A homogenate was produced with five up and 
down strokes with a Potter Elvejhem homogeniser. Light microscopy 
confirmed that the cells were disrupted by this procedure. 
Daunorubicin was added to 1 ml of homogenate as an internal
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standard. One ml of tissue homogenate was treated with 33% (W/V)
silver nitrate (0.2 ml per homogenate) for 10 min at 4°C in the 
vortex evaporator with vigourous shaking (the vigourous shaking was 
important for good recovery). Immediately 5 volumes of chloroform/ 
propan-2-ol (2:1) was added to the homogenate mixture and the parent 
drugs and their metabolites were extracted by vortexing for a 
further 30 minutes. Three phases were separated by centrifugation 
at 1000 rpm for 15 minutes. The upper aqueous phase was discarded 
by aspiration, the lower organic phase was decanted over the middle 
tissue pellet into a clean test tube and evaporated to dryness in 
the vortex evaporator at 40°C and 25 mm Hg of vacuum. The dry 
extracts were reconstituted in a small volume of methanol and were 
then ready for HPLC separation as previously described (sec 2.2).
Pharmacokinetic analyses The area under the curve (AUC^^) f°r 
plasma and tissue drug content was calculated by the trapezoidal 
rule. Pharmacokinetic parameters were estimated by non linear least 
squares fitting using an in-house programme based on the Marquhardt 
algorithm (Bevington, 1978). Statistical comparisons were made 
using paired Student’s t-test with Bonferroni correction where 
applicable.
Electron Microscopic assessment of cardiac toxicity Wistar rats 
were treated by intravenous administration of 15 mg/Kg adriamycin or 
4*-deoxy. This dose of drug has been previously associated with the 
development of a subacute cardiomyopathy in rats 1 - 4  days 
following treatment with adriamycin. Two days after treatment the 
rats were sacrificed, their hearts dissected and the ventricular 
apices fixed in freshly prepared 1.5% glutaraldehyde and post-fixed 
in 1% osmium tetroxide. They were then dehydrated in graded 
ethanols and embedded in Epon-Araldite.
Thin sections, cut at 250-500 A° with a Reichert OmU-2 
ultramicrotome, were mounted on Formvar-coated 200-mesh copper 
grids. These sections were stained with lead citrate and uranyl 
acetate and examined with a Jeoko 100B electron microscope. In 
addition the hearts of 3 untreated rats were similarly prepared for 
electron microscopic study and served as histologic controls.
4.3 Results
Fluorescence localisation studies Under the conditions described, 
adriamycin fluoresces orange. Initial examination of formalin- 
fixed tumour sections stained with haematoxylin and eosin revealed 
an anaplastic carcinoma, with no central necrosis and a peripheral, 
annular complex of small arterioles and capillaries (Fig 4.1). 
Fluorescent studies with the fluorescein conjugated antibody 
directed against endothelial factor VIII showed a similar 
distribution of blood vessels, mainly on the peripheral rim of the 
tumour, although centrally penetrating arterioles and capillaries 
were demonstrated in the tumour core.
Drug specific fluorescence was detected only within cell 
nuclei of the various organs examined. Both adriamycin and 
4'-deoxy appeared to be homogeneously distributed in heart muscle, 
liver, kidney and skeletal muscle with relatively intense 
intranuclear fluorescence (fig 4.2 - 4.4). The situation was
markely different in the tumour with a faint ring of drug specific
fluorescence seen on the periphery of the tumour, and a marked 
diffusion gradient declining from the periphery to the centre of the 
tumour (fig 4.5). The staining associated with 4’-deoxy was 
relatively more intense (implying a greater amount of drug bound) 
and had penetrated further from the vascular annulus (fig 4.6)
Drug pharmacokinetics The relevant kinetic parameters are summarised 
in tables 4.1 - 4.3. Peak drug levels in tumour and heart for 
4,-deoxy are significantly higher (P< 0.05) despite a lower peak
serum concentration compared to adriamycin. Total drug exposure, as
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assessed by the area under the concentration time curve, for tumour, 
heart and plasma was greater following treatment with 4'-deoxy. The 
pattern of intracardiac metabolism of the two drugs was different. 
There was significant (75%) metabolism of adriamycin to the 
7-deoxyaglycones of the parent drug and adriamycinol. This 
contrasts with the cardiac fate of 4'-deoxy, where over 90% of the 
parent drug was present unchanged.
Electron Microscopic assessment of cardiac toxicity
Ultrastructural alterations in rat myocardium in response to 
anthracycline treatment have already been described (Mettler et al, 
1977)• Mitochondrial swelling, vacuolation and dense body formation 
were seen following administration of adriamycin and 4'-deoxy which 
conforms to the histopathological changes previously reported (fig 
4.7 and 4.8). Using the scoring systems introduced by Bertazzoli et 
al (1979), the extent of cardiac damage was quantified and found to 
be similar for the two drugs (approximately, grade 0.5)
Antitumour efficacy of adriamycin and 41-deoxy The tumour volumes 
following treatment with equimolar doses of adriamycin and 4*-deoxy 
are summarised in table 4.4. Adriamycin does not significantly alter 
the tumour growth kinetics of the MC-40A fibrosarcoma relative to 
control. In stark contrast, there is no further growth of the 
tumours following treatment with 4 '-deoxy. All of the controls 
survived, whereas one in the adriamycin group and 3 in the 4'-deoxy 
group had died by the time of final tumour assessment.
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The lipophilic analogue, 4'-deoxy, has a different disposition 
in tumour bearing rats than adriamycin. Despite a lower peak 
concentration in plasma, 4'-deoxy achieves significantly higher 
peak levels in tumour and heart. Total drug exposure, estimated by 
the area under the plasma or tissue concentration time curve, is 
higher for plasma, heart and tumour.
In addition to these pharmacokinetic parameters which imply 
increased drug penetration, 4'-deoxy appears to diffuse further 
into the tumour substance from the external vascular ring. It is 
possible that 4'-deoxy is more diffusable by virtue of its higher 
oil-water partition coefficient and can leave the vascular 
compartment with relatively greater ease.
By virtue of these properties, if there is a relationship 
between clonogenic cell kill and intracellular drug levels, then 
4'-deoxy would be expected to be more potent than adriamycin at 
equitoxic doses.
It is apparent from the tumour growth delay experiments that 
4'-deoxy is significantly (p< 0.01) more active than adriamycin in 
equimolar doses in this tumour model. However, there were more drug 
associated deaths (30%) in the 4'-deoxy treated groups than in 
adriamycin treated (10%) by the experiment's end point. The ideal 
doses to compare cytotoxic drugs in vivo are equitoxic as this gives 
a logical basis for deriving relative therapeutic ratios. The 
equitoxic dose is usually dependent upon the relative degree of 
myelosuppression caused rather than on chronic toxicity such as 
cardiomyopathy. Cassaza (1975) has reported that 4'-deoxy is more 
active in a number of murine tumours in vivo, at equitoxic doses, 
than adriamycin.
This has potential therapeutic implications in man. There is a 
growing awareness that adjuvant chemotherapy following debulking of 
the primary tumour by surgery or sterilisation by radiation can have 
survival benefits. This situation has been best documented by
Bonadonna et al (1976) following adjuvant chemotherapy with 
cyclophosphamide, methotrexate and 5-Fluorouracil for breast cancer 
patients treated by mastectomy. If the multicellular spheroid is a 
representative model for a micrometastasis prior to vascularisation, 
precisely the stage of disease that adjuvant chemotherapy is aimed 
at, then it is apparent that significant drug penetration barriers 
and associated cytotoxic drug resistance will be present at this 
early peroid in the metastasis' natural history. In view of our 
findings on the penetration properties of 4'-deoxy in vitro and in 
vivo, then a case might well be made for adjuvant trials of 
chemotherapy inclusive of lipophilic cytotoxic analogues.
Adriamycin-induced cardiomyopathy is a severe total 
dose-limiting side effect in patients treated with this powerful
anti-neoplastic agent. Several inconclusive studies have been
performed on animals and man to clarify the mechanism of toxicity 
and to find putative protective substances for this untoward side 
effect (Unverferth et al, 1982). New anthracycline analogues are
tested extensively in animal model systems predictive of
cardiotoxicity in the hope that chemical modification of the drug's 
stucture will produce an active cogener which is less cardiotoxic. 
On the basis of electron microscopic examination of rat ventricular 
apices it appears that adriamycin and 4'-deoxy are equally 
cardiotoxic when administered in equimolar doses.
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There is thought to be an association between peak 
intracardiac drug levels and the development of cardiomyopathy, yet 
peak levels of 4*-deoxy are considerably higher than those of 
adriamycin. The pattern of intracardiac drug metabolism also 
differs; there is extensive conversion of adriamycin to its 
7-deoxyaglycone, whereas 4'-deoxy is largely unchanged. Although 
one would expect 4'-deoxy to be more cardiotoxic on the basis of 
cardiac pharmacokinetics, this may be offset by differential 
metabolism of adriamycin to its 7-deoxyaglycone. A hypothesis has 
been advanced that a portion of the cardiac toxic effects are 
mediated by free radical production within myocytes from the 
anthracycline (Bachur, 1979). The 7-deoxyaglycones are considered 
metabolic "markers" of intracellular free radical production and it 
would appear that adriamycin is being metabolised within rat cardiac 
cells via a pathway that would ensure damaging free radical 
production. There is no evidence of free radical production at the 
concentrations seen within cardiac cells for 4'-deoxy, which may 
produce its cardiotoxic effect by a different mechanism (Unverferth 
et al, 1982).
One would have predicted from the preceding in vitro 
experiments that 4'-deoxy would have different penetration and 
pharmacokinetic characteristics on the basis of its physico­
chemical properties. Although intratumoural levels of 4'-deoxy were 
higher than the corresponding values for adriamycin, peak 
intracardiac levels were increased also. According to the 
pharmacokinetic hypothesis, 4'-deoxy would have been expected to 
cause a greater degree of cardiotoxicity. Possibly by virtue of a 
different pathway of cardiac drug metabolism, adriamycin and 
4'-deoxy are similarly toxic to heart myocytes.
When extrapolating from an in vitro situation, such as the 
multicellular spheroid model, it is important to recognise the 
importance of the therapeutic ratio (effective dose/toxic dose) in 
vivo. If a novel analogue of a pre-existing cytotoxic agent were 
introduced which was considerably more potent than the parent 
compound in vitro, this need not translate into a clinically, 
exploitable improvement in the therapeutic ratio, if the drug's 
toxicity is similarly enhanced.
With regard to cardiomyopathy, one would redict that 4'-deoxy 
would have a greater therapeutic ratio in rats bearing the MC40A 
sarcoma.
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Day Control Adriamycin 4'-deoxydoxorubicin
0 100 100 100
2 120 + 4 123 + 6 112 + 6
4 156 + 10 148 + 14 109 + 3
6 192 + 11 180 + 12 121 + 14
8 210 + 9 198 + 18 108 + 16
10 262 + 22 232 + 17 107 + 14
Table 4.4 The percentage increase in tumour volume (taking mean 
pretreatment volumes as 100%) with time following 
intravenous treatment with adriamycin (10 mg/kg),
4'-deoxydoxorubicin (10 mg/kg) or normal saline 
(control). There was no statistical difference in tumour 
growth rates between control and adriamycin treated 
animals, whereas 4'-deoxy virtually abolished tumour 
growth (p < 0.01, compared to control at all time points 
after day 2).
Figure 4.
Figure 4.
1 Haematoxylin and eosin stained section of the MC40 
tumour. Note the vascular annulus on the periphery of 
the tumour (magnification x 100)
2 Fluorescent photomicrography of rat cardiac muscle
following infusion of adriamycin (magnification x 100)
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Figure 4.3 Fluorescent photomicrograph of rat liver following 
infusion of adriamycin (magnification x 100)
Figure 4.4 Fluorescent photomicrograph of rat skeletal muscle
following infusion of adriamycin (magnification x 100)
Figure 4.5 Fluorescent photomicrograph of adriamycin treated MC40A 
tumour. The drug is localised predominantly on the 
periphery of the tumour, with relatively poor diffusion 
into the centre of the tumour (magnification x 25).
Figure 4.6 Fluorescent photomicrograph of 4'-deoxy treated MC40A 
tumour. The drug has diffused further into the 
central, avascular region of the tumour compared to 
adriamycin (magnification x 25)
Figure 4.7 Electron micrograph of adriamycin treated rat heart 
showing mitochondrial swelling and disruption 
(magnification x 5900)
■ i m m
Figure 4.8 Electron micrograph of adriamycin treated rat heart
showing a high power view of mitochondrial vesiculation 
(magnification x 43000)
CHAPTER 5 /
Cellular accumulation and spheroid penetration of lipophilic 
anthracycline analogues
5.1. IOTRODOCITON
If, as hypothesised, adriamycin diffuses through the lipid 
domain of the cell membrane, then its rate of diffusion will obey 
Pick's first law in which the flux per unit area of a molecule 
through the membrane (J) depends on the diffusion coefficient of 
the molecule (D) and its concentration gradient across the membrane 
dc/dx:
J = D dc/dx
D is a complex term and depends on the physico-chemical 
properties of the drug molecule and the biological membrane. The 
drug membrane permeability barrier might be overcome by altering 
the properties of the drug or by increasing membrane fluidity.
There are three properties of a drug molecule that are central 
to the issue of its transmembrane movement; its lipid solublity, 
the extent to which it is ionised and its molecular size. 
Together, these factors determine whether a molecule will move from 
one biological compartment to another separated by a membranous 
structure, and provide some basis for predicting the rate and 
extent of such transmembrane inter compartment movement (Brodie,
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The lattice model of membrane diffusion (fig 5.1) adequately 
accounts for rates of transport of many non-electrolytes. In this 
model diffusion, occurs by the movement of the permeant molecule 
into a "vacancy" in the lattice structure of the membrane (fig
5.1). The principle energetic barrier to diffusion in this case is 
the activation energy required to move the substrate from the 
aqueous phase into the apolar environment of the phospholipid 
bilayer. There is a correlation between membrane permeability and 
the hydrophobicity of the permeant molecule. The postulated 
"vacancies" in the lattice are envisaged as temporary 
discontinuities created by lateral movement of the phospholipid 
molecules. High rates of diffusion, and therefore increased 
membrane fluidity, can occur by pretreating the membrane with 
surface active or "chaotropic" agents. (Wilson, 1978).
In this chapter, the cellular uptake and cytototoxicity of a 
series of lipophilic anthracycline analogues is described. A 
number of cytotoxic agents and drugs (eg anti-emetics) have 
membrane surface active properties, yet the pharmocodynamics of 
anticancer drug interaction at the level of the cell membrane has 
not been generally considered. In this section, the effect of a 
number of common anticancer drugs and agents which might be 
coadministered in combination with adriamycin, on adriamycin 
transport is examined.
/88
5.2 Materials and Methods
Monolayer and Spheroid culture - the cell culture conditions used 
for monolayer and spheroids have been described (sec 3.2)
Determination of monolayer clonogenic survival and spheroid growth . 
delay.
The details of the clonogenic assay and means of assessing 
spheroid growth delay have been previously annotated (sec 3.2). The 
anthracyclines used in this study were kindly supplied by Farmitalia 
Carol Erba Ltd., and were dissolved in normal saline prior to use. 
The chemical structures are shown in figure 5.2. Tumour cells (both 
monolayer and spheroid) were treated over a wide concentration range 
specific to the individual drug being studied; adriamycin (0.1 - 10
i^g/ml); daunomycin, (0.1 - 10 yjg/ml); 4-demethoxydaunorubicin (0.05 
- 5 yjg/ml); 4'-deoxy-4'-iododoxorubicin (0.0005 - 1 i^g/ml);
4'-deoxydoxorubicin (0.1 - 10 ^ g/ml)•
Determination of intracellular anthracycline levels
Monolayers of L-DAN cells were exposed to a fixed drug con­
centration for one hour. The drug concentration differed for each 
analogue used, and the final intracellular drug concentration was 
scaled up, as if the cells had been exposed to an external 
concentration of 5pg/ml. The cells were then harvested, counted and 
intracellular anthracycline concentrations were measured as 
previously described (sec 2.2). Additional experiments were 
performed wherein adriamycin (5pg/ml) was conincubated with putative 
"penetration enhancers" for one hour. The concentration of the drug 
used was calculated from its known pharmacokinetics to correspond to 
maximum achievable plasma levels at clinically employed doses;
metoclopramide (2/ug/ml); prochloperazine (10/ug/ml); chlorpromzine
*”6 “6 (50/ug/ml); hydrocortisone (2 x 10 M); dexamethasone (10 M).
An identical series of experiments was performed with cytotoxic
agents commonly used in combination therapy with adriamycin?
bleomycin (10/ug/ml)*VP-16 (50 /ug/ml); cis platinum (10 ug/ml);
~8vincristine (5 x 10 M)? 5-fluorouracil (200/ug/ml); methotrexate 
-5(10 M); flavone acetic acid (IJ4975), (200/ag/ml). Each experiment 
was repeated five times and statistical analysis was by Students 
t-test with Bonferonni's correction, where applicable. Correlation 
analyses were done using Spearmans rank correlation test.
Fluorescent microscopic assessment of intraspheroid drug penetration 
Spheroids of 400 pm in diameter were incubated at a fixed drug 
concentration for one hour. Thereafter the spheroids were prepared 
for fluorescent microscopy as previously described (sec 3.2)
5.3 RESULTS / 90
Intracellular anthracycline levels
The intracellular concentrations achieved for the different 
anthracycline analogues are summarised in table 5.1 with the 
butanol/Tris-buffer partition coefficients of the individual 
compounds. There was a degree of intracellular metabolism of 
daunomycin (50%) and 4-demethoxydaunomycin (15%) to their 
respective alcohols, but in the interest of clarity, only total 
intracellular drug (i.e. parent drug + alcohol) levels are 
presented. There would appear to be a linear relationship between 
hydrophobicity, as estimated by the oil/water partition 
coefficient, and intracellular drug concentration (r = 0.99, P < 
0.01)
The only drug which significantly affected adriamycin uptake 
in the coincubation experiments was flavone acetic acid (Table
5.2). This inhibited the cellular accumulation of adriamycin such 
that total intracellular adriamycin levels were < 10% of control.
Relative cytotoxicity of the anthracycline analogues
The composite spheroid growth curve analysis for each of the 
anthracyclines used are shown in tables 5.3 - 5.7.
The clonogenic ID^ for monolayers, and the drug 
concentration which produced a doubling in growth delay relative to 
control is summarised for individual analogues in table 5.8 (the 
monolayer cell survival curves are shown in figure 5.3).
There is no correlation between monolayer potency and the oil/ 
water partition coefficients, but this relationship is confounded 
mainly by 4’-deoxydoxorubicin.
There is a linear correlation (r = 0.99f p < 0.01) between log 
[concentration which doubles growth delay relative to control] and 
log [ oil/water partition coefficient] and log [intracellular drug 
level].
Spheroid drug diffusion gradients; fluorescent microscopy
Under the experimental conditions used, it was possible to 
differentiate the pattern of spheroid penetration for adriamycin 
from those of the hydrophobic analogues. It was not, however, 
possible to distinguish the diffusion patterns of the analogues from 
each other. By one hour, the drugs had diffused to a depth of 6 - 8 
cell layers from the external spheroid surface (Fig 5.4). All 
visible drug was bound to the nucleus and there was no evidence of 
cytoplasmic fluorescence. Due to the relative insensitivity of 
fluorescence microscopy and the variable quenching caused by nuclear 
binding of different anthracyclines (Crooke and Dunvernoy, 1980; 
Egorin et al, 1980) it was not possible to make a quantitative 
analysis of relative diffusion for the lipophilic derivatives.
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The more hydrophobic the molecule the greater the degree of 
cellular drug uptake. This is consistent with the hypothesis that 
the anthracyclines diffuse through the lipid domain of the cell 
membrane (Dalmark and Storm), 1981). According to Fick's law, the 
more lipophilic anthracycline cogeners have higher diffusion 
coefficients (D) than the parent compound. There is a correlation 
between membrane permeability and hydrophobicity which can be 
explained by the lattice theory of transmembrane diffusion. The 
more lipophilic the molecule, the less activation energy is required 
to move the substrate from the aqueous phase into the relatively 
apolar environment of the membrane. Therefore the bioenergetics of 
transmembrane diffusion favours the more hydrophobic derivatives.
As mentioned previously, the oil/water partition coefficient is not 
the only determinant of transcellular drug movement. The 
anthracyclines have an ionisable amino group on the daunosamine 
sugar with a pKa of 7.5 - 8. The degree of ionisation of the drug 
molecule is important, as a charged drug moiety will not cross the 
membrane. The dependence of adriamcyin uptake on external pH has 
already been demonstrated (sec 3.3). The sigmoid curve of 
intracellular drug vs pH (fig 3.2a) conforms to the calculated curve 
of degree of drug ionisation vs pH (fig 3.2b).
The third variable which orders transmembrane inter- 
compartmental drug transfer is molecular size. Prabhakar et al 
(1986) have correlated in vitro antitumour activity (inhibition of 
growth of human lymphoblastic leukaemia cells) of several adriamycin 
analogues with the van der Waals volume of the substituents. 
Activity was also found to be well correlated with first-order 
valence molecular connectivity index. On the basis of their 
findings, the authors concluded that cytotoxic activity would be
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affected by the steric influence and to some extent by the
electronic configuration of the substituent groups appended to the 
tetracyclic ring backbone.
There does not appear to be a direct relationship between 
lipophilicity and cytotoxic efficacy in monolayer. Although a log 
linear relationship between intracellular adriamycin concentration 
and clonogenic cell kill exists, (sec 2.2) this is not the case for 
4'-deoxy. This presumably accounts for the disparity between the 
oil/water partition coefficient and the degree of clonogenic cell 
kill, at least for 4*-deoxy. The mode of action of the 
anthracyclines is thought to depend on the ability of these drugs to 
intercalate into DNA and thus prevent DNA synthesis (Dano et al, 
1972; Rozencweig et al, 1975 Arlandini et al, 1977? Bachur, 1979? 
Cassaza, 1979; Cassaza, 1980; Schwartz, 1983; Terasaki, 1984). 
However, there is no association between the DNA binding constants 
of individual analogues and cytotoxic end points in vitro (Israel 
and Potti, 1982) Given the disparity between cytotoxic efficacy and 
relative affinity for ENA intercalation, this implies either that 
the anthracyclines have different modes of cytotoxic action, or that 
some other stage in the interaction between drug and intact cell is 
rate limiting. Alberts and Dorr (1982) have reviewed the many 
proposed mechanisms of action of adriamycin, including intracellular 
free radical production, anti-mitochondrial effects and surface 
active membrane properties, yet concluded that inhibition of DNA 
synthesis still seems the most likely means of the drug exerting its 
cytocidal effects. This also seems to be the case for the other 
anthracycline compounds used in this study (Cassazza, 1980).
The rate limiting step with regard to cellular accumulation of 
drug molecules is transmembrane transport. In this respect, the 
cell membrane can be likened to a sheet of synthetic rubber such is 
its ability to retard drug diffusion. As demonstrated, there is a 
relationship between hydrophobicity and intracellular drug levels, 
but not between hydrophobicity and clonogenic cell survival. By 
syllogistic reasoning this implies that there is not a direct 
relationship between intracellular drug levels and clonogenic cell 
survival (correlation r = 0.23, p >  0.4). It is apparent that of 
the relatively limited series of derivatives tested, 4'-deoxy would 
appear to behave differently from the other analogues and confounds 
the correlations between intracellular drug concentration and 
hydrophobicity with monolayer clonogenic survival. One major 
reported difference between 4*-deoxy and the other cogeners is its 
inability to form free radicals in vitro, and it is possible that 
this difference obfuscates a structure-activity relationship in 
monolayer culture.
There does appear to be a correlation between the log of the 
concentration of drug which doubles spheroid growth delay and log 
oil/water partition coefficient and (r = 0.99, P <  0.01) and log 
intracellular drug levels in monolayer (r = 0.99, P <0.01). It was 
impossible, however, to correlate spheroid diffusion depth with
either of these parameters due to the insensitivity of the
fluorescent microscopic technique used. Presumably, the greater the
ease with which the drug molecules cross the cell membrane, the
greater will be the degree of intercompartmental membrane transport 
within the spheroid. The more drug which is taken up into the 
external spheroid ring, the greater the concentration gradient which
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which will drive diffusion of the drug into the substance of the 
spheroid.
There was no enhancement of adriamycin uptake by any of the 
drugs listed in Table 5.2. It is of note that flavone acetic acid, 
an experimental therapeutic agent which is currently undergoing 
phase I clinical assessment, significantly decreased adriamycin 
uptake. The mechanism of this is unknown, however the class of
flavonoid aglycones are thought to inhibit membrane transport of a 
variety of compounds and this may explain its inhibition of
adriamycin uptake.
There have been reports of chlorpromazine, lignocaine and
octanol (Dalmark and Storm, 1981) increasing the permeability of
tumour cell membranes to adriamycin, but at concentrations far in 
excess of these pharmacologically achievable. It is unlikely 
therefore, that there is any significant pharmacodynamic interaction 
between adriamycin and the drugs listed in Table 5.2, in common 
clinical practice.
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Compound Intracellular Oil/Water
Concentration Partition
5
(ng/10 cells) Coefficient
Adriamycin 14+2 6.3
Daunomycin 154 + 27 17.8
4’-deoxydoxorubicin 170 +15 15.0
4-demethoxydaunomycin 400 +67 32.3
4!-iodo,4f-deoxydoxorubicin 1961 + 156 126
Table 5.1 Intracellular drug levels (+ standard deviation) 
following monolayer exposure to equivalent of 5 jag/ml for one hour. 
Oil/water partitioning was carried out with butanol/tris-buffer.
Compound
Adriamycin alone 
Adriamycin + VP16 
Adriamycin + 5-fluorouracil 
Adriamycin + bleomycin 
Adriamycin + cisplatin 
Adriamycin + methotrexate 
Adriamycin + flavone acetic acid 
Adriamycin + metoclopr amide 
Adriamycin + prochlorperazine 
Adriamycin + hydrocortisone 
Adriamycin + chlorpromazine 
Adriamycin + dexamethasone
TABLE 5.2 Intracellular Adriamycin 
following co-incubation with a
/ 97
Intracellular 
Adriamycin 
Concentration 
(ng/10^  cells)
14 + 2
16 +2.5 
18 + 4
13 + 3.2
17 +5.2 
1 1 + 6.2
0.9 + 0.25 (p < 0.01)
15+3.2
14 + 4.1 
13 + 1.9
18 + 3.4 
18 +3.6
levels (+^ standard deviation) 
variety of different drugs.
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Compound Monolayer Spheroid Growth
Clonogenic ID9Q Delay
(ug/ml) (ug/ml)
Adriamycin 2.2 10
Daunorubicin 1 0.6
4'-deoxydoxorubicin 2.1 0.68
4-demethoxydaunorubicin 0.1 0.05
4'-deoxy, 4*-iododoxorubicin 0.007 0.004
TABLE 5.8 The relative potency of anthracycline compounds in 
vitro, assessed by monolayer clonogenic cell survival and spheroid 
growth delay. The drug concentration producing a doubling in 
spheroid growth delay relative to control is quoted.
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Figure 5.4 Fluorescent photomicrograph of an L-DAN spheroid
exposed to 4'-deoxy, 4'-iododoxorubicin 2 ug/ml for 1 
hour (magnification x 100)
CHAPTER 6 /
The effect of the non-ionic surfactant, Brij 30 on cellular uptake 
and cytotoxicity of adriamycin in monolayer and spheroid culture 
systems.
6.1 INTRODCfCTION
Studies in several mammalian cell culture systems have shown 
that experimentally developed resistance to adriamycin is associated 
with reduced membrane permeability to the drug (Riehm and Biedler, 
1971; Dano et al, 1972; Kaye and Merry, 1985). Levin*s calculations 
(Levin et al, 1980) showed that the slow diffusion of drug into 
tumour could limit the effectiveness of chemotherapy, and have 
encouraged the search for penetration enhancers (Azmin et al, 1985). 
Many non-ionic surfactants particularly of the poly(oxyethylene) 
alkyl and aryl ether class interact with biological membranes 
increasing their permeability and allowing increased trans-membrane 
solute transport (Florence et al, 1984). While the mechanisms are 
not fully understood, interaction of the surfactant molecules with 
the membrane occurs following adsorption and the disruption of 
membrane integrity and function is at the centre of many of their 
observed biological effects (Florence, 1981).
Not all surfactants are capable of inducing increased membrane 
fluidity and drug transport. However the nonionic detergent 
polysorbate 80 has been reported to increase the absorption of 
methotrexate (Azmin et al, 1985) and to potentiate the anti­
neoplastic effect of adriamycin in vivo and in vitro (Riehm and 
Biedler, 1972; Seeber et al, 1978; Cassazza et al, 1978). These 
effects were attributed to an increase in cellular drug uptake in" 
the presence of the detergent, presumably mediated by altered 
membrane fluidity (Seeber et al, 1978).
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In this chapter we have assessed the effect of an alkyl ether 
polyoxyethylated surfactant, one of a series of surfactants studied 
to determine the relationship between structure and influence on 
membrane permeability (Watters et al, 1982) on the cellular 
accumulation and cytotoxicity of adriamycin in monolayer and 
spheroid culture systems. A lauryl ether, Brij 30, was chosen 
because of the finding that this alkyl chain length was optimum in 
enhancing permeability in other test systems.
6.2. Materials and Methods / 119
Monolayer culture: The L-DAN cell line was derived from our own 
patient with squamous lung cancer. The cells were maintained as a 
monolayer in exponential growth in Ham's FlO/t)MEM (50:50) with 8mM 
NaHCO^ supplemented with foetal calf serum. Chronic mouse myeloid 
leukaemia (MlRl cell line) and mouse granulocyte cells were 
maintained in RPMI 1640 medium supplemented with 10 -15% foetal calf 
serum.
Conditions of drug exposure and determination of cell survival; The 
monolayers were exposed to adriamycin (Farmitalia Carlo Erba), Brij 
30 (Atlas Chemical Industries, England) and a combination of the two 
over a range of concentrations for one hour. The clonogenic dose 
response curve for Brij 30 was determined over a concentration range 
of 0.003-0.3ul/ml. During combined treatment, the concentration of 
Brij 30 was fixed and the concentration of adriamycin varied from 
0.1-10/ug/ml.
After treatment, L-DAN monolayers were harvested with 0.25% 
trypsin in PBS, centrifuged and washed with ice cold medium. The 
cells were then diluted in medium and seeded at 200 cell/ml in 5 cm 
petri dishes. The plates were incubated for 12 days in a humid 2% 
CC>2 atmosphere. The colonies were then fixed and stained with 
crystal violet and colonies of >40 cells were counted. Clonogenic 
cell survival for the mouse granulocytes and MlRl cells was 
determined from an agar capillary method (Maurer and Henry, 1976). 
Following the usual convention, the cloning efficiency of the 
untreated cells was normalised to 100% and the cloning efficiency of 
the treated cels was expressed as a percentage of control survival.
Spheroid culture: L-DAN monolayers were disaggregated enzymatically 
with 0.25% trypsin in PBS and the resultant cell suspension used to 
provide cells for initiation of tumour spheroids, using the "agar 
underlay" static method (Yuhas et al, 1977).
Cytotoxic drug efficacy was assessed by measuring spheroid 
growth delay and disaggregated spheroid clonogenic survival. 
Spheroids from two flasks were pooled and a number of glass 
universal tubes were prepared each containing 200-300 spheroids with 
a mean diameter of approximately 350 Aim. The spheroids were treated 
with similar drug concentrations as used in monolayer for one hour 
at 37°C with intermittent agitation. At the end of this period 
the spheroids were allowed to sediment, the drug containing medium 
was removed and they were washed with fresh, ice cold medium. The 
spheroids were then resuspended in medium and subdivided for assays 
of response.
For clonogenic assay approximately half of the spheroids were, 
incubated with 0.125% trypsin in PBS for 15 minutes at 37°C, after 
which the trypsin was removed and replaced with fresh medium. The 
spheroids were then mechanically disaggregated to a single cell 
suspension by repeated pipetting. The clonogenic assay was 
performed as previously described.
For spheroid growth delay measurement spheroids from the other 
group were transferred to agar coated wells in a plastic tissue 
culture multidish with one spheroid per well. Twenty-four spheroids 
were taken from each treatment group and measurements of cross- 
sectional area of individual spheroids were made twice weekly using 
a Micromeasurements image analysis system coupled via a television
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camera to an inverted optical microscope. The area measurements 
were subsequently converted to volumes, assuming spherical geometry. 
Sequential estimates of median spheroid volume were made and growth 
delay could be calculated from the time taken for median spheroid 
volume to increase by a factor of ten above initial size (Twentyman, 
1980).
Determination of intracellular drug levels: L-DAN monolayers were
exposed to adriamycin (5/ug/ml) and Brij 30 (0.01/Ug/ml) for varying 
times (0.5-2 hours). The cells were then washed twice with ice cold 
PBS, harvested by brief trypsinisation, counted (Coulter Counter 
Ltd, England) and resuspended in distilled water. Adriamycin was 
then extracted and measured by reversed phase high pressure liquid 
chromatography with fluorescence detection, as previously described 
(Cummings et al, 1984). Adriamycin levels were expressed as
5
ng/10 cells. Drug uptake curves were fitted by the method of 
least squares.
Fluorescent and electron microscopy: Intact spheroids aproximately
500/um in diameter were exposed to adriamycin (£ug/ml) + Brij 30 
(O.O^ ug/ml) for varying times. The spheroids were then washed to 
remove loosely bound drug, placed in gelatin capsules filled with 
OCT embedding gel (Lurker Labs Ltd) and frozen in liquid nitrogen. 
Thin cryotome sections (£um) were mounted in uvinert and examined 
under a Polyvar fluorescent microscope ( A  excitation = 468 nm;
X emission = 550 nm).
The effect of Brij 30 on the morphology and ultrastructure of 
L-DAN cells was assessed by electron microscopy. Monolayers of 
intact cells were exposed to Brij 30 (0.01-1 jfL/ml) for one hour 
and the cells subsequently processed for routine electron microscopy 
(sec 4.2). Untreated L-DAN spheroids were prepared for electron 
microscopy in order to demonstrate the compactness of cellular 
stacking and intercellular junctional apposition.
6.3 Results / 123
Intracellular drug levels: the relationship between intracellular
adriamycin levels and time, for a fixed external drug concentration, 
is curvilinear. The intracellular adriamycin levels are 
significantly higher for the L-DAN cell line, at all time points 
following combined treatment with the surfactant (fig 6.1).
Monolayer survival: clonogenic cell survival after treatment with 
adriamycin + Brij 30 is summarised in Fig 6.2 for the L-DAN cell 
line, MlRl cell line and mouse granulocytes. The adriamycin 
concentration found to inhibit 90% clonogenic cell survival (ID^ q) 
for each cell line is summarised in table 6.1.
L-DAN: Brij 30 alone, at the concentration used in these experiments 
(O.Olul/ml), reduced clonogenic survival by approximately 10% so 
this was subtracted from the figure attributed to combined 
treatment. Clearly, combined treatment significantly enhances the 
cytotoxicity of adriamycin.
MlRl/Mouse granulocytes: the concentration of Brij 30 (0.07ul/ml)
used in these experiments was not cytotoxic. There is no difference 
in the response of myeloid leukaemic cells or granulocytes to 
adriamycin over the concentration range used. The combination of 
adriamycin and Brij 30 is significantly more toxic to both cell 
lines than adriamcyin alone, however the tumour cells are more 
adversely affected than the granulocytes. It would appear that Brij 
30 selectively enhances the activity of adriamycin in the tumour 
cell line at lower drug concentrations (0.1-0.6ug/ml) by 
approximately 20% (figure 6.2).
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L-DAN spheroid survival; growth delay over a range of adriamycin 
concentrations was determined in the presence and absence of Brij 30 
(Table 6.2). Co-treatment with the surfactant induces significantly 
longer growth delays at each adriamycin concentration.
Disaggregated spheroid clonogenic cell survival is higher than 
for monolayer at identical adriamycin concentrations implying that 
adoption of the spheroid configuration confers a degree of 
resistance to adriamycin (Fig 6.3). Treatment with Brij 30 
significantly improves (P<0.05 at drug concentrations O.^ ug/ml) the 
clonogenic cell kill of adriamycin, but it is still less than that 
found in monolayer (Fig 6.3).
Fluorescence and electron microscopy: it was possible to determine
qualitatively the degree of adriamycin penetration into the 
spheroids. The spheroids are approximately 16-20 cell layers in 
diameter, and adriamycin had diffused into the outer 3-4 layers 
after incubation for one hour. Brij 30 increased the penetration 
depth to approximately 6-7 cell layers.
Electron microscopy revealed that Brij 30 alone caused 
significant ultrastructural alterations to L-DAN cells which were 
concentration dependent. These ranged from complete cytolysis 
(1 /ul/ml) to minimal structural membrane changes in the plasma 
membrane and intracytoplasmic organelles at 0.01/ul/ml (figs 6.4 - 
6.6).
Low power electron micrographs of L-DAN spheroids show that the 
cells are packed in a compact fashion with little intercellular 
space (fig 6.7). High power views show a variety of intercellular 
junctions including gap junctions and "tight" desmosomal or maculae 
adherentes junctions (fig 6.8)
6.4 Discussion /125
In this present study we have shown that combined treatment 
with Brij 30 enhances the cellular uptake of adriamycin and 
significantly improves its cytotoxicity in monolayer (human lung and 
mouse myeloma) and spheroid culture systems. This effect is 
probably mediated by facilitated cellular uptake of adriamycin, 
which we found to be 2 - 3 fold higher in L-DAN monolayers in the 
presence of surfactant.
If the clonogenic survival vs concentration curves were redrawn 
as sigmoid pharmacological dose response curves (fig 6.9), it is
apparent that the effect of Brij 30 is to shift the curves to the 
left, which is compatible with its proposed mode of action in 
increasing membrane permeability to adriamycin.
It is interesting to note that despite virtually identical 
sensitivity to adriamycin alone, the combination of adriamycin and 
Brij 30 is differentially cytotoxic to the leukaemia cells; as can 
be seen in fig 6.9 this effect occurs at clinically relevant
concentrations of adriamycin (Benjamin et al, 1977).
The electron microscopic data suggest that the surfactant is
altering membrane structure in seme way, although the technique is
too insensitive to give detailed information on the degree of 
membrane disruption. Spheroid fluorescent microscopy indicated that 
Brij 30 tends to increase the depth to which adriamycin can 
penetrate, vve have not examined the penetration properties of the 
surfactant itself, however it presumably diffuses into the spheroid 
to a depth of at least 6 - 7  cell layers where it could increase 
intercellular diffusion of adriamycin.
TWEEN 80 /127
Sum of W, XY, Z is 20; 
R is (C17H33) COO
W
H,
Brij 30 = CH3 (CH2)1q CHg - JpCHgCH^ 4 OH;
Brij 36T = CH3 (CH2)10 CH2 - [0CH2 CH^ 1Q OH.
Surfactants are amphipathic molecules and their relative
hydrophobicity is described by a hydrophile-liphophile balance (HLB)
number; the higher the HLM number, the more hydrophilic the
molecule. Tween 80 (HLB = 14.9) and Brij 36T (HLB = 15.2) are
evidently more hydrophilic than Brij 30 (HLB = 9.7). The optimum
HLB for surfactant-mediated increases in permeability depends on the
nature of the membrane as well as the surfactant series and drug
under study (Florence et al, 1984). The lower the HLB the greater
the affinity of the surfactant activity is limited by aqueous
insolubility. Steric factors also intrude. The areas/molecule of
2 2Brij 30 and 36T are 0.38 nm and 1.09 nm respectively. The 
latter was most active on the isolated rabbit gastric mucosa 
(Walters et al, 1982) and on adsorption through rat nasal mucosa 
(Hirai et al, 1981).
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The lattice model for drug diffusion across the cell membrane 
has been previously described (sec 5.1). Cell treatment with 
chaotropic agents such as amphipathic surfactants would be expected 
to increase membrane fluidity and lateral diffusion of phospho­
lipids. This increases the statistical probability of transient 
gaps in the membrane appearing to allow greater drug diffusion into 
the cell.
It is possible that this increased cellular permeability 
accounts for the apparent synergy of Brij 30 with adriamycin in the 
cell lines studied. There is a small but significant enhancement of 
the activity of adriamycin + Brij 30 against tumour cells relative 
to normal granulocytes. This could reflect a differential membrane 
response to the surfactant by normal and neoplastic cells and may 
impart a degree of selectivity to combination treatment with 
surfactant and cytotoxic.
In summary, we have demonstrated that the non-ionic 
polyoxyethylated surfactant Brij 30 enhances cellular accumulation 
of adriamycin and its antineoplastic activity in vitro.
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Cell Line Adriamycin ID q^ (ug/ml)
+
Brij 30 Brij 30
L-DAN 0.6 2.4 a
MIRI 0.4 1.9 a, b
Mouse granulocytes 0.8 1.5 a, b
TABLE 6.1 Adriamycin ID^ g (+ Brij 30) in monolayers. The ID^ g
values were derived by non linear least squres fit of the 
clonogenic survival data, a: Significant difference
(p< 0.05) by Student*s t-test, comparing IDgg's + Brij 
30, b: significant difference (p< 0.05) by Student's 
t-test, comparing ID^ q 1s for MIRI and mouse 
granulocytes (+ Brij 30)
Adriamycin Growth delay (days)
Concentration (ug/ml) + -
Brij 30 Brij 30
Control 9 (7.2 - 10) 8.1 (6.3 - 8.9)
2 16.8 (13.1 - 17.6) 11.5 (10 - 14.2)
5 19 (18 - 21.5) 13 (12 - 14.9)
10 35 (28.6 - 37.2) 17.3 (15.4 - 18.3)
15 37 (27.3 - 40.1) 18.2 (16.1 - 19.4)
TABLE 6.2 Spheroid growth delay in response to adriamycin (+ Brij
30). The values in brackets encompass the 95% confidence
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Figure
ADRIAMYCIN
i.i
10-
60
MINUTES
120
The time course of cellular accumulation of adriamycin (fixed drug 
concentration of 5 ug/ml)
Adriamycin alone -------
Adriamycin + Brij 30 )0.01 ul/ml) -----
Each point represents the mean of 5 experiments and the vertical bars 
represent 1 standard deviation
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CLONOGENIC
SURVIVAL
100
100
60
100
0-50*20-1
ADRIAMYCIN (ug/ml)
Figure 6.2 Clonogenic cell survival curves for
A LDAN cell line 
B MRI cell line
C Normal grnulocytes
Adriamycin alone •----
Adriamycin + Brij 30 o—
Each, point is the mean of 5 experiments and the vertical bass represents 1 standard 
deviation
CELL SURVIVAL
(%)
10“
Spheroids  ---------
Monolayer —
X Adriamycin 
•  Adriamycin +  BRIJ
01
53 4210
ADRIAMYCIN (ug/ml)
Figure 6.3 Clonogenic cell survival in monolayers and 
disaggregated spheroids following treatment 
with adriamycin + Brij 30
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Figure 6.4 Electron micrograph of L-DAN cells exposed in monolayer 
to Brij 30, 1 pl/ml. There is evidence of complete 
cytolysis (magnification x 4900)
i
4
Figure 6.5 Electron micrograph of L-DAN cells exposed in monolayer 
to Brij 30, 0.1 pl/ml. There is evidence of 
external/internal membrane disruption and clumping of 
nuclear chromatin (magnification x 2950).
Jt *■ '■
jf A'
Figure 6.6 Electron micrograph of L-DAN cells exposed in monolayer 
to Brij 30, 0.01 ul/ml. There is evidence of minor 
alterations in intracellular membrane structure 
(magnification x 4900)
Figure 6.7 Low power electron micrograph of L-DAN spheroids
showing compact cellular packing (magnification x 1300)
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Figure 6.8 High power electron micrograph of L-DAN spheroids 
showing close membrane apposition and a demosomal 
junction (magnification x 9800)
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CHAPTER 7
'ftie pharmacokinetics and disposition of adriamycin following its 
administration, in solution or encapsulated in niosomal vesicles, 
to tumour bearing nude mice.
Introduction
Many attempts have been made to alter the specificity and 
pharmacokinetics of cytotoxic agents by complexing them with macro- 
molecular carriers (chapter 9) such as liposomes. These are 
microscopic particles composed of one or more phospholipid bilayer 
membranes which can carry lipid soluble drugs in their bilayers and 
water soluble drugs in their aqueous compartments. The liposomes 
vary in size, the number of enveloping lamellae and in lipid 
composition, although the common bilayer-forming lipids which are 
used include the phosphatidyl cholines, sphingomyelins, phosphatidyl 
serines and phosphatidylethanolamines. Liposomes have been shown to 
react with cells in several different ways such as fusion, 
endocytosis, stable adsorption on the cell surface and by lipid 
transfer. Numerous hypothetical reasons have been advanced for 
considering liposome use, some of which are more compelling than 
others: reduction of cytotoxic drug clearance and prolongation of
its circulation; protection of the host against liposome contents eg 
reduction of adriamycin cardiotoxicity; delivery of drugs designed 
for endocytic uptake; circumvention of cell membrane permeability 
barriers by liposome - cell fusion; physical targeting by 
introducing the liposomes into a specific compartment of the body eg 
peritoneal cavity; natural targeting to cells of the reticulo­
endothelial system, which tend to remove liposomes by phagocytosis. 
These considerations must be balanced by the problems and 
limitations of liposomes as carriers for cytotoxic drugs; a 
variable, but usually high, uptake of liposomes in the liver and
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spleen? inability of liposmes to escape from the vascular
compartment; vesicular disruption by serum components; liposomes are 
potentially antigenic and they can evoke an immunogenic response 
from the host.
A number of studies have demonstrated enhanced cytotoxicity of 
liposome encapusulated drugs in vitro (Kimelberg and Mayhew, 1978).
It has been proposed that this effect is mediated via increased
cellular drug uptake by a fusional or endocytic process. However, 
it is unlikely that these processes would occur in vivo, where 
systemically administered liposomes would be mainly confined to the 
vascular compartment or phagocytosed by cells of the reticulo­
endothelial system. There is in vivo evidence, however, that
administration of liposomes to tumour bearing rodents decreases 
adriamycin associated cardiac toxicity without loss of therapeutic 
effect (Forssen and Tokes, 1979 and 1983? Olson et al, 1982). A 
preliminary report of a phase I clinical study with liposome- 
associated adriamycin indicated that liposome administration is 
feasible and has potential advantages over free adriamycin with 
regard to some of its immediate toxic side effects (Gabizon et al, 
1986).
In association with the French drug company Loreal, Professor 
A.T. Florence, Department of Pharmacy, University of Strathclyde has 
developed a novel drug carrier termed the niosome, which has 
properties similar to the liposome.
Niosomes are multilamellar vesicles made of surfactant and 
cholesterol and are neutral, whereas liposomes are composed of 
phospholipids and are therefore usually charged. In view of
previous results with the surfactant Brij 30, it was incorporated 
into the niosomes which were used to encapsulate adriamycin. The 
effect of niosomal encapsulation on the pharmacokinetics and 
disposition of adriamycin in tumour xenograft bearing nude mice is 
described.
7.2 Materials and Methods /l40
Preparation and characterisation of niosomes
Niosomes (fig 7.1) were prepared by the hand-shaken and ether- 
injection techniques (i) Hand shaken technique; 150 /umol of 
surfactant or surfactant/cholesterol mixture was dissolved in 
diethylether (10 ml) in a 50 ml round-bottomed flask, and the ether 
evaporated on a rotory evaporator (Buchli) at 40 °C under reduced 
pressure. The dried film was hydrated with water or with 200 mM 
aqueous solutions of Carboxyfluorescein (CF) (3-5 ml) at 50 °C, 
for 15 min, with gentle agitation, (ii) Ether injection technique? 
150 /umol of surfactant or surfactant/cholesterol mixture was 
dissolved in diethylether (20 ml) and injected slowly (0.25 ml 
min )^ through a 14-gauge needle into water or aqueous solutions 
of CF (200 mM, 5 ml) maintained at 60 °C. After injection of
solvent the system was maintained at 60 °C for 1 h to ensure 
complete evaporation. For in vitro experiments the hydrating 
solution contained 0.2 mg ml  ^adriamycin whereas for the in vivo 
studies, where the hand-shaken technique was used exlusively, the 
solution was usually 2-5 nq ml  ^adriamycin. Hand shaken niosomes 
were 987 + 123 nm in diameter and had approximately 6 concentric 
layers (fig 7.1).
Separation of free and entrapped adriamycin
Each niosome sample was suspended in a final volume of 
approximately 20 ml PBS (pH 7.2) and centrifuged (7000 g, 20°C,
30 min). Supernatants were discarded and the pellets washed three 
times with buffer and resuspended in PBS (25ml).
Estimation of adriamycin concentration with niosomes
The niosome suspension (5ml) was adjusted to pH5 to ionise the 
adriamycin, shaken with chloroform (10ml, 30 sec) in a 50ml
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funnel, and after 5 min the two phases were separated. The upper, 
cloudy, aqueous phase contained adriamycin and the lower chloroform 
the surfactant. The aqueous phase was clarified by gentle addition 
of double distilled water (5ml) then collected and adriamycin 
concentration analysed directly by HPLC (sec 2.2). The chloroform 
layer was evaporated to dryness, avoiding heat, and was 
reconstituted in methanol (1ml) prior to immediate analysis. It was 
therefore possible to derive the amount of adriamycin entrapped by 
the niosomes.
N
Murine pharmacokinetic studies
WIL, a human squamous lung tumour xenograft characterised in 
our department, was serially passaged in lOOmg fragments into nude 
mice bred from our own colony. The tumour fragments were inserted 
into a surgically created subcutaneous pouch on the right flank of 
ether anaesthetised mice. The wound was closed with surgical clips, 
which were removed seven days later. The mice were housed in a 
sterile environment and received food and water ad libitum. 
Approximately 3 weeks after initial transplantation, the flank 
tumours were approximately 1 cm in diameter and easily palpable.
Free adriamycin or niosome encapsulated adriamycin was administered 
intravenously via the tail vein in a dose of lOmg/Kg, in a volume of 
0.1 - 0.2 ml. The mice were sacrificed by exsanguination under 
light ether anaesthesia at specified time points thereafter (30 
mins, 1 hour, 2 hours, 4 hours, 12 hours, 24 hours and 48 hours).
Four mice were used per time point.
Blood samples (1 - 2 ml per mouse) were collected into lithium 
heparin tubes, centrifuged (2,000 rpm for 5 minutes) and the plasma 
separated and stored until analysis at -20°C. The liver, kidneys, 
heart and tumour were dissected out, washed once in ice cold
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phosphate buffered saline and blotted dry. Individual tissues were 
then frozen rapidly in liquid nitrogen and stored at -20°C until 
analysis.
Drug analysis — this has been previously described in detail (sec 
4.2)
Mathematical Analysis - Plasma drug levels were fitted to a 2 
compartment open model by the technique of least squares based on 
the Marquhardt algorhythm using an "in house" programme. It was 
therefore possible to calculate the drugs clearance and volume of 
distribution (central and peripheral compartments) from the 
microscopic rate constants. This model is described in further 
detail in chapter 11. Tissue drug levels were expressed as ug 
drug/gram of tissue, and the area under the concentration-time 
curves (AUC) was calculated by the by trapezoidal rule. 
Statistical comparisons were made by two way analysis of variance or 
Student's t-test with Bonferroni correction where appropriate.
7.3 Results
Peak drug levels and tissue AUC's are outlined in table 7.1. 
The plasma concentration-time curve is shown in fig 7.2. The plasma 
decay profile of free adriamycin was best fitted by a biexponential
Ci. _ o  o j .
equation; plasma concentration, c = 165e * .+ 0.91e .
Peak levels of free adriamycin were significantly higher than with 
niosomal adriamycin. Niosomal adriamycin levels were maintained at 
roughly constant levels for the first 4 hours following bolus 
injection and declined monoexponentially thereafter.
Plasma adriamycin levels were significantly higher between 4 - 
12 hours with the niosomes, and this was reflected in a higher mean 
AUC. As it is impossible to take multiple plasma samples from 
single mice, it is impossible to statistically compare AUCfs as this 
parameter is derived from single samples from multiple animals. 
Nevertheless, the form of the plasma concentration profiles differs. 
Adriamycin clearance (free = 0.51/hour; niosomes = 0.381/hour), 
volume of distribution (free = 5.71; niosomes = 1.11) and plasma 
half lives (free = 8 hours; niosomes = 2 hours) were calculated. 
The high volume of distribution indicates extensive tissue binding 
of adriamycin. The terminal half life of adriamycin in plasma is 
thought to represent diffusion of the drug from binding sites in the 
tissue compartments.
The niosomal adriamycin half life is shorter than for free 
drug. It is possible that the terminal phase of adriamycin 
disposition is occuring below the limit of our assay (lng/ml) and 
that the concentration-time curve has been shifted to the left with 
niosomal drug administration. This situation is similar to
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the pharmacokinetics of adriamycin when administered by infusion, 
with a decreased peak, constant levels for the duration of infusion 
followed by a monoexponential decline.
Hepatic tissue levels of adriamycin were similar regardless of 
its mode of administration (fig 7.3). The AUC's, peak hepatic 
levels (Table 7.1) and tissue half lives (17 hours) for adriamycin 
were statistically indistinguishable. The degree of hepatic 
metabolism of adriamycin was greater for niosome encapsulated 
adriamycin (figs 7.4). Peak levels of the 7-deoxyaglycone of 
adriamycinol are significantly higher (p< 0.05) after niosome
treatment. The degree of hepatic metabolism can be defined by the 
ratio.
AUC adriamycin /AUC adriamycin + AUC metabolites x 100%
The % metabolism ratio for niosomal adriamycin (85%) is less 
than for free adriamycin (95%) despite similar AUC's for parent 
drug, implying greater hepatic uptake and metabolism for adriamycin 
encapsulated in niosomes.
Peak renal levels are significantly (p< 0.05) higher after free 
adriamycin (fig 7.5). The renal AUC is also higher (table 7.1) and 
the tissue half life rather shorter (20.6 hours vs 36.4 hours) than 
for niosomal adriamycin. There was a minor degree (<5%) of 
netabolism of adriamycin to the deoxyaglycones of parent drug and 
adriamycinol, which was similar for free and niosomal drug.
Cardiac adriamycin concentrations were significantly and 
consistently higher throughout the concentration time profile (fig 
7.6) in the free adriamycin group. Peak level, AUC and the terminal
half life (36 hours vs 10.8 hours) were elevated over those values 
observed with the niosomes (Table 7.1). There was no significant 
intracardiac metabolism of adriamycin, with either preparation of 
the drug.
Intratumoural drug levels were similar with regard to peak 
levels and AUC (fig 7.7). The terminal half life is apparently 
prolonged in mice treated with free adriamycin, however this 
accounts for only a small fraction of the total AUC (<5%). It is 
possible that there is a terminal slower phase of drug decline in 
niosome treated mice, which is below the limit of assay sensitivity. 
No intratumoural metabolites were detected.
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Encapsulation of adriamycin in niosome vesicles alters the 
pharmacokinetics and disposition of the drug in tumour xenograft 
bearing nude mice. The significant differences, relative to 
administration of adriamycin solution, are as follows; prolonged 
release of drug from the plasma compartment with lower peak drug 
levels; lower peak cardiac levels of adriamycin with a shorter 
tissue half life and decreased cardiac AUC; a greater degree of 
hepatic metabolism to inactive 7-deoxyaglycones.
One would expect that intratumoural drug content, probably best 
expressed as AUC, would bear some relationship to the cytotoxic 
effects of the drug. On the basis of the kinetic data, one would 
expect that the two forms of the drug would therefore have similar 
cytotoxic efficacy.
Cardiac levels of adriamycin are significantly lower with the 
niosomal drug preparation. Peak plasma levels of adriamycin are 
thought to be directly correlated with the development of 
cardiomyopathy and this concept underlay the use of prolonged' 
infusions of adriamycin in chemotherapeutic regimens in order to 
decrease peak drug levels and hence the chance of cardiac damage 
(Unverferth, 1982). The niosomes decreased peak plasma and cardiac 
adriamycin concentrations and total cardiac drug exposure (as 
assessed by the lowered tissue AUC)• Although the cardiac toxicity 
of the niosomes relative to equimolar doses of adriamycin has not 
been formally assessed, it is possible, on pharmacokinetic grounds, 
that the niosomes will be relatively cardioprotective. It may be 
possible, then, to give greater doses as the therapeutic ratio would 
be improved by formulation of adriamycin in niosomal form and thus 
improve their cytotoxic action.
/ 147
Although the niosomes are constitutively and physicochemically 
distinct from liposomes, the results reported in this chapter are,
on the whole, similar to previously executed studies employing
liposomes as the carrier vehicle for adriamycin.
Forssen and Tokes (1979) and Olsen et al (1982) reported
reduced cardiac uptake of encapsulated adriamycin in association
with less electron microscopic evidence of cardiomyopathic damage 
than that due to free drug.
The degree of hepatic uptake and metabolism was greater with 
the niosome proparation. As with other carriers, a considerable 
percentage of intravenously administered liposomes are removed from 
the circulation by reticuloendothelial cells in the liver and 
spleen. It would appear that the Kupffer cells of the liver trap 
niosomes in a similar manner, and promote the intrahepatic 
metabolism and deactivation of adriamycin.
It can be concluded, therefore, that niosome encapsulated
adriamycin has a different tissue distribution than free adriamycin, 
with the predominant effect being of lowered cardiac drug 
concentrations. It is possible, as total dose limitation in tumours 
is related to cardiotoxicity that even a modest reduction in cardio- 
toxicity could enable an increase in the total dose of adriamycin
administered or a reduction in the likelihood of toxicity.
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FREE ADRIAMYCIN
Peak level AUC
(o-oo)
Plasma 0.1 + 0.01 0.4
Heart 11.7 + 0.10 110
Kidney 24 + 1.8 295
Liver 27.9 + 1.9 195
Tumour 4.5 + 0.5 32.1
NIOSOME ENCAPSULATED
ADRIAMYCIN
Peak level AUC
(o-oo)
0.075 + 0.01* 0.53
5 + 0.27* 43.6
11.3+1.2* 160
14.2+1.5 175
7.5 + 0.9 48
TABLE 7.1
Comparative total tissue and plasma contents of adriamycin following 
administration of free or niosome encapsulated drug. Peak levels 
are expressed as /ug/g jfrug/ml for plasma) and the AUC as /ug/g 
tissue x hour (hg/ml x hour for plasma) + 1 standard deviation.
*Indicates significant (p< 0.05) differences in peak levels.
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Figure 7.1 Phase contrast photomicrograph of a multilamellar 
niosome containing adriamycin (magnification x 100)
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Figure
P la sm a  
Concentration (pg//ml)
\ _
k 8 12 16 20 2L
Time (hours)
.2 Plasma concentration-time profile following treatment with free 
adriamycin ) and niosome encapsulated adriamycin (O ). Each 
point is the mean of 4 mice and the vertical bar denotes 1 
standard deviation, i^mplies a statistically significant difference 
at the p <  0.05 level.
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Adriamycin  
C o n c en t ra t io n  (ug/g)
Time (h ou rs )
Figure 7.3 Hepatic concentration-time profile following treatment with free 
adriamycin (•) or niosome bound adriamycin (O ). Each point is 
the mean of 4 mice and the vertical bar denotes 1 standard 
deviation.
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Figure 7.5 Renal concentration-time profile following treatment with free 
adriamycin (• ) or niosome encapsulated adriamycin (O ). Each 
point is the mean of 4 mice and the vertical bar denotes 1 
standard deviation. *Stastical difference at p<0.05 level.
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Adriamycin  
C o n c en t ra t io n  (ug /g )
10-
Time (h o u rs )
Figure 7.6 Cardiac concentration time profile following treatment with free 
adriamycin (• ) or niosome bound adriamycin ( O). Each point 
is the mean of 4 mice and the vertical bar denotes 1 standard 
deviation. S^tatistical difference at p<0.05 level 
^^ Statistical difference at p<.0.01 level
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CHAPTER 8 /156
Antitumour activity of niosome encapsulated adriamycin in 
monolayer, spheroid and xenograft.
8.1 Introduction
The pharmacokinetics and disposition of niosome encapsulated 
adriamycin were described in the previous chapter. Studies on the 
in vitro cytotoxicity of liposome encapsulated drugs have been 
conflicting, with evidence of decreased, increased or maintained 
activity (reviewed by Kimelberg and Mayhew, 1978). In this section, 
the cytotoxic activity of equimolar doses of adriamycin in free 
solution or entrapped in niosomes is examined in monolayer, spheroid 
and solid xenografts of human lung tumour cells.
8.2 Materials and Methods
Nisome preparation - niosome preparation was described in chapter 7.
Monolayer and spheroid culture systems L-DAN monolayers and 
spheroids were grown as previously described. Standard monolayer 
clonogenic assays were performed after exposure to free or niosome 
bound adriamycin for 1 hour over a wide concentration range (0.1 - 
10 pg/ml). Spheroid growth delay was assessed following identical 
drug exposures.
Tumour growth delay in vivo - WIL, the squamous lung tumour 
xenograft used in the pharmacokinetic studies, was serially passaged 
in 100 mg fragments into nude mice bred in our own laboratory. The 
tumour fragments were inserted into a surgically created 
subcutaneous pouch on the flank of ether anaesthetised mice. The 
wound was closed with surgical clips which were removed 1 week 
later. The mice were housed in a sterile environment and received
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food and water ad libitum.. Approximately 3 weeks after initial 
tumour transplantation, the flank tumours were approximately 1 cm in 
diameter and easily palpable. Three groups of tumour bearing mice
(10 mice in each group) were treated with; free adriamycin 7.5
mg/kg; niosome encapsulated adriamycin 7.5 mg/kg (an equimolar dose 
of adriamycin); normal saline as control. Thereafter the tumour 
volume was measured 3 times per week for 3 weeks. Volume was 
assessed by measuring the 2 largest diameters with specially adapted
3
calipers and converting these measurements into volume (cm )
*
using the formula Vol = 4/3 Tr r^ . There is a direct linear
correlation between tumour volume and tumour weight (y = 1.28 x =
0.87; n = 66, r = 0.96) which was characterised by Dr S Merry, fig
8.1.
8.3 Results /
Monolayer clonoqenic survival - the survival curves are shown in 
fig 8.2. There is no difference in clonogenic cell kill between 
niosomes and adriamycin with respective ID9Qs of 2.1/ug/ml and 
2.2/ug/ml.
Spheroid growth delay - the growth delay data has been tabulated 
(table 8.1). Growth delay is similar at each drug concentration 
whether free or entrapped in niosomes.
Tumour growth delay in vivo The percentage increase in tumour weight 
(relative to pretreatment values) has been plotted against time for 
each of the 3 treatment groups (fig 8.3). Tumour growth in the 
control group increased exponentially. The growth delay (i.e. the 
time taken for the tumour weight to double) was longer for 
adriamycin (15 days) and niosomal adriamycin (11 days) than for 
control (5.8 days). Tumour weights were not statistically different 
comparing free adriamycin vs Niosomes, but both the adriamycin 
treated groups tended to be significantly smaller than controls (p< 
0.05) (Table 8.2)
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8.4 Discussion /160
The cytotoxic activity of adriamycin is maintained in vitro and 
in vivo despite encapsulation in niosomal vesicles. The niosomes 
can probably interact with cells in vitro in several different ways. 
Adsorption is likely to be a non specific 1 ip id-surf actant 
interaction occuring at the cell surface. This could allow locally 
high concentrations of drug to accumulate at the cell surface by 
diffusion out of the niosome and thus promote cellular uptake of 
drug. Alternatively, adsorption may lead to endocytic incorporation 
of the niosomes and their contents into the cell. It is possible 
that the Brij 30 surfactant component of the niosome could diffuse 
from the vesicle and interact with the tumour cell membrane to 
increase its permeability to adriamycin. It is most likely, 
however, that endocytosis is the most important form of interaction. 
Following endocytic uptake, the vesicles are presumably degraded 
within the cell thus allowing the drug to diffuse to its site of 
action within the nucleus.
Spheroid growth delay for niosomal adriamycin is virtually the 
same as for free adriamycin. It is difficult to envisage niosomes 
disrupting spheroid structure or diffusing within the spheroid 
substance therefore presumably enough adriamycin is taken up by the 
external cell annulus to allow production of a sufficiently large 
intraspheroidal concentration gradient to match the growth delay 
associated with free adriamycin.
It is unlikely that any of these mechanisms of niosome-cell 
interaction occur in vivo. Niosomes, like liposomes, are too large 
to efficiently pass across endothelial and epithelial cell layers or 
across intact basement membranes. The distribution of the 
micro-encapsulated drug therefore depends on its mode of 
administration.
/ 161
This vehicle will lend itself to a regional chemotherapeutic 
approach, where one objective is to confine the drug to a specific 
body compartment eg intraperitoneal, intrarticular, intrathecal 
and intrarterial chemotherapy.
It has been shown (sec 7.3) that the niosomes circulate for a 
prolonged period in the blood stream and maintain relatively high 
adriamycin levels before declining thereafter with a reduction in 
adriamycin clearance. This has profound efects on intracardiac drug 
levels, which are lower, whilst maintaining tumour drug levels. The 
antineoplastic efficacy of free and niosomal adriamycin in equimolar 
doses is similar in vivo. This would be predicted from the 
pharmacokinetic study as the AUC for tumour drug exposure was 
likewise independent of the form in which adriamycin was 
administered. In view of the finding of identical antitumour
activity in this model with free and niosome entrapped adriamcyin, 
and the alluded association between peak intracardiac adriamycin 
levels and the subsequent development of cardiomyopathy, then it 
would appear that niosome encapsulated adriamycin has a higher 
therapeutic ratio than free adriamycin.
As previously detailed, the pharmacokinetics of diffusion of 
active drug from slow release pharmaceutical preparations such as 
niosomes, can be mimicked by intravenous infusion. It would be 
possible to design an adriamycin infusion which would achieve a 
similar plasma profile to that seen with the niosomes. There are 
pragmatic problems with infusional chemotherapy but with the advent 
of new pump designs and improved methods of vascular access, this is
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becoming a relatively common means of administering cytotoxic drugs. 
There is evidence to suggest, in man, that adriamycin infusions are 
less cardiotoxic than bolus injection, with maintenance of 
antineoplastic activity. (Unverferth et al, 1982).
It remains to be tested whether niosomal encapsulation of 
adriamycin offers any significant biological advantages over 
altering the drug schedule.
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MEDIAN SPHEROID GROWTH 
DELAY (days)
Drug concentration Free Adriamycin Niosome - Adriamycin 
(jjg/ml)
0 (control) 8.1 (6.3 - 8.9) 7.6 (6.5- 8.3)
1 11.5 (10 - 14.2) 12 (11.0 - 13.3)
5 13.1 (12 - 14.9) 12.9 (11.8 - 14.2)
10 17.3 (15.4 - 18.3) 17.2 (16.0 - 19.3)
20 17.4 (16.1 -19.4) 18.1 (16.9 - 19.6)
Table 8.1
Spheroid growth delay in response to treatment with free and niosome 
bound adriamycin. The figures in brackets correspond to 95% 
confidence limits around the median value.
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% Increase in tumour volume
Day Control Free Adriamycin Niosome - Adriamycin
0 100 100 100
2 135 + 9 100 + 10a'd 130 + 6a'd
4 163 + 8 142 + 7a,d 145 + lla'd
7 232 + 27 163 + 19a'b 177 + 8a,d
9 242 + 18 143 + •6a,b 186 + 13a,d
11 262 + 41 160 + 29a,b 204 + 23a,d
15 354 + 11 203 + 21a'C 216 + 18a,c
17 456 + 26 250 + 18a'C 265 + 24a,c
Table 8.2
The percentage increase in tumour volume (taking mean pretreatment 
volumes as 100%) with time, following treatment with free adriamycin 
(10 mg/Kg, intravenous), niosome encapsulated adriamycin (10 mg/Kg, 
intravenous), or normal saline (control) .
Student's t-test values; a, N.S. comparing free vs niosomes
b, p<0.05 comparing free vs control
c, p<0.01 comparing free and niosome vs 
control
d, N.S. comparing niosome vs control
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Figure 8.2 Clonogenic survival of LDAN monolayers following treatment with 
free adriamycin ( • m  ) or niosome encapsulated adriamcyin 
( •-— • ). Each point is the mean of 4 experiments and the 
vertical bar denotes 1 standard deviation.
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CHAPTER 9 /
Cellular uptake and cytotoxicity of daunonycin and a complex of 
daunomycin - low density lipoprotein in monolayer and spheroid
9.1 Introduction
Numerous attempts have been made to enhance the selectivity of 
antineoplastic agents by linking them to a carrier moiety. Human 
albumin in microspherical form, macroaggregated protein (Szeberke et 
al,1972) monoclonal antibodies (Seto et al, 1982), DNA-anthracycline 
complexes (Deprez-De Campaneere et al, 1979), drug - hormone 
conjugates (Varga et al, 1977; Kaneko, 1981) and encapsulation of 
the cytotoxic agent in liposomes (Abra et al, 1983; Gregariadis, 
1976)• There is no doubt that in most cases the pharmacokinetics of 
the anticancer drug are altered, sometimes favourably, with a 
resultant decrement in toxicity. However a number of problems 
remain to be overcome to provide a clinically useful carrier system:
a) specificity of the carrier for tumour cells in vivo
b) stability of the carrier complex in vivo
c) release of the active agent at the target site
d) non specific uptake of exogenous material by the reticulo­
endothelial system (Poste, 1983).
e) adverse immunological reactions to the exogenous carrier. 
Low density lipoprotein (LDL) is the major cholesterol-carrying
lipoprotein in human plasma. The LDL particles contain a lipid core 
of approximately 1,500 ester molecules surrounded by a polar shell 
of free cholesterol, phospholipids and protein (apoprotein B). It 
has been shown that a variety of human cell types express cell 
surface receptors for IDL. After binding to the receptor, an auto­
regulated sequence of events occurs which culminates in lysosomal 
degradation of the lipoprotein and subsequent release of the
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cholesterol for use in the cell. Recent reports indicate that cells 
which are undergoing active cell division show a greater LDL 
receptor activity than non-dividing cells. For example, Gal et al 
(1981) have demonstrated in vitro that replicating epidermoid 
cervical carcinoma (EC-50) cells metabolise LDL some 20 times faster 
than cervical fibroblasts. Similar evidence has accumulated for 
leukaemic cells relative to normal marrow stem cells.
Attempts have been made to utilise the LDL-receptor pathway by 
complexing LDL with cytotoxic drugs. LDL-aclacinomycin A is 
effective against human glioma cells in culture and DDL-methotrexate 
covalent complex is active against murine leukaemia cells in vitro. 
Iwanik et al (1984) have prepared an LDL-daunomycin complex in which 
daunomycin appears to be located in the surface region and the 
hydrophobic domain of the LDL particle. They demonstrated 
significantly higher cell associated levels of daunomycin after 
treatment of P388 leukaemic cell lines with the LDL-daunomycin 
complex, than after exposure to free daunomycin under similar 
conditions.
In this study, the LDL-receptor activity of the IHDAN cell line 
has been characterised and the cellular uptake, metabolism and 
cytotoxic efficacy of LDL-daunomycin complex has been examined in 
monolayer and spheroid.
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9.2 Materials and Methods
Isolation of lipoprotein This follows the method of Patsch et 
al 1974. Briefly, human plasma was isolated from venous blood 
(100 ml) drawn from normolipidaemic adults after overnight fasting. 
LDL was extracted by rate zonal ultracentrifugation using a linear 
NaBr gradient in a Sorvall refrigerated centrifuge. The LDL was' 
then dialysed and its purity checked by SDS-polyacrylamide gel 
electrophoresis. Iodination of lipoproteins were accomplished by 
the iodine monochloride method, modified by Bilheimer et at (1972).
LDL-daunomycin complex formation This follows the method of Iwanik 
et al (1984). Daunomycin in methanol was evaporated to dryness in a 
Buchler Vortex Evaporator and resuspended with 2-5 mg of LDL in 1 ml 
of LDL buffer. The mixture was stirred with a Teflon-coated stirrer 
for 2 hours in the dark at room temperature. The mixture was then 
passed down a sephadex G-120-15 column equilibrated in LDL buffer, 
which separated the free from complex associated daunomycin. The 
complex was then sterilised by passage through a 0.44 urn Millex 
Millipore filter.
125Cellular degradation of I-LDL
6Isolated L-DAN cells (approximately 2 x 10 ) were incubated 
125for 24 hours with I -LDL in 1 ml of F10DMEM culture medium, at
37°C in humidified air containing 5% C02. Blank incubations 
were performed under identical condition in the absence of cells. 
The degradation of LDL was determined from the appearance of non 
iodide trichloracetic acid (TCA) soluble material in the incubation 
medium, as described by Goldstein et al (1974). In brief
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125undegraded high molecular weight I-LDL in the medium was
precipitated by TCA. After centrifugation, free iodide was
125separated from degradation fragments of I-LDL m  the
supernatant by oxidation with H2°2 an  ^ extraction with
chloroform. An aliquot of the aqueous phase was then assayed for
125radioactivity to determine the degradation of I-LDL.
125I-LDL Binding to intact cells
5 .2 x 10 cells were grown m  petn dishes, and on Day 7 after
24 hours of growth in medium containing lipoprotein-deficient serum,
*
the medium was removed from each dish and replaced with 2 ml of
Medium A, consisting of Eagle's minimum essential medium containing
penicillin and streptomycin; 20mM Glycine, pH 7.4; and 5 mg of
lipo-protein-deficient serum, and the indicated amounts of
125I-LDL protein and native LDL protein. After incubation on a 
rotatory shaker (80 oscillations per min) in air at 37°, the
medium was removed and all subsequent operations were carried out at 
4° in a cold room. Each monolayer was washed 3 times in rapid 
succession with 3 ml of buffer containing 50 mM. Tris-HCl, pH 7.4; 
0.15 M NaCl; and 6 mg of bovine serum albumin, after which a further 
3 ml of the same buffer was added and the monolayer was incubated 
-for 2 min. This latter step was repeated once, each monolayer was 
washed finally with 3 ml of buffer containing 50 mM Tris-HCl, ph 7.4 
and 0.15 M NaCL, and the cells were removed from the dish by 
dissolution in 1 ml of 0.1 N NaOH. Aliquots of 500 yil were removed 
from each dish for scintillation counting in a gamma counter and 
50-jil aliquots were taken for measurement of protein concentration. 
In all figures, each point represents the value obtained from a
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single dish and is expressed as the counts per min of bound
per mg of total cell protein. Each dish contained 350 to 500 ug of
125total cell protein. Duplicate determination of I-LDL binding 
varied by less than 10% of the mean values.
Conditions of cell growth - LDAN monolayers and spheroids were 
grown as previously described.
Assays of cytotoxicity - monolayer clonogenic survival and spheroid 
growth delay were assessed after exposure to daunomycin or 
LDL-daunomycin, for 1 hour over a concentration range of 0.1 - 5
Cellular localisation of daunomycin by fluorescence microscopy
Monolayers of L-DAN in the exponential phase of growth were 
exposed to LDL-daunomycin or free drug at a concentration of 5 pg/ml 
for up to 2 hours. The monolayers were washed twice with ice cold 
PBS, wet mounted and examined under the Polyvar fluorescent 
microscope (filters set at the same for adriamycin). Spheroids were 
prepared for fluorescent microscopy as previously described (sec 
3.2) after exposure to daunomycin or LDL-dauno, 5 jig/ml for 1 hour. 
Determination of the intracellular concentrations of daunomycin and 
its metabolites
Monolayers of L-DAN in the exponential phase of growth were 
treated with complexed or free drug at an external concentration of 
10 jig/ml for varying times (15 minutes to 2 hours). The cells were 
washed twice with ice cold PBS, harvested by brief trypsinisation 
(0.25%) counted, and then resuspended in 2 ml of distilled f^ O. 
Parent drug and its metabolites were then extracted and measured by 
HPI£ with fluorescence detection, as previously described (sec 4.2). 
Drug levels were expressed as ng/10 cells and drug accumulation 
curves were approximated by non-linear least squares fitting.
9.3 Results /173
Cellular accumulation and metabolism of daunomycin
Cellular uptake of daunomycin and LDL-daunomycin proceeded 
rapidly and approached equilibrium by approximately 3 hours. It is 
of note that parent drug concentrations, on a cellular basis are 
similar and statistically indistinguishable at each experimental 
time point (table 9.1; figure 9.1) regardless of whether free drug 
or the complex was used. The degree of intracellular drug 
metabolism, however, differed markedly. Daunorubicinol which is 
synthesised by a ubiquitous cytoplasmic NADPH reductase from parent 
drug was the chief metabolite formed (at the highest drug 
concentration, small amounts of the deoxyaglycone of daunorubicinol 
were measurable). During prolonged incubation with free drug (> 90 
minutes) daunorubicinol predominated over parent drug (table 9.1). 
If parent drug is expressed as a per centage of total intracellular 
drug i.e. daunomycin/daunomycin + daunomycinol x 100%, then it is 
apparent that relatively less daunomycin is converted to the alcohol 
after treatment of the cells with the LDL-daunomycin complex.
The total cellular drug content (daunomycin + daunomycinol), is 
higher after exposure of the cells to free daunomycin. (Table 9.1)
Intracellular localisation of drug by fluoresence microscopy
The subcellular distribution of daunomycin is apparently 
independent of its mode of delivery to the cell. Daunomycin is 
present in a granular distribution within the cytoplasm, the nucleus 
and the nuclear membrane. This is similar to the fluorescent 
staining pattern previously reported by 4'-deoxy (sec 2.3). The 
LDL-daunomycin complex does not appear to markedly alter the 
intracellular disposition of the cytotoxic agent despite
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the fact that the drug' is presented to the cell in a markedly 
different physico-chemical state, and presumably enters the cells 
by a different pathway.
Sectional analysis of spheroids by fluorescent microscopy showed 
that visible drug was nuclear bound and had diffused slightly 
further into the spheroid after presentation bound to LDL.
Cytotoxicity to monolayer and spheroid
The monolayer clonogenic cell survival curves for daunomycin 
and LDL-daunomycin are shown in figure 9.2. The degree of cell kill 
produced by both drugs is similar (XD^ q daunomycin, 1.0 jig/ml; 
ID q^ LDL-daunomycin 0.7 jag/ml). The cell survival curves are 
biphasic with a point of inflection at 5 jag/ml.
Spheroid growth delay data is summarised in Table 9.2. 
LDL-daunomycin induces significantly longer growth delays at equal 
medium concentrations than free daunomycin. Despite similar 
monolayer clonogenic survival curves the disaggregated spheroid 
clonogenic survival curves reveal that LDL-dauno is significantly 
more active in spheroids than free daunomycin if one compares 
relative clonogenic cell survival at concentrations of 5 jag/ml (p < 
0.05).
125I-LDL degradation and binding to L-DAN cells
125The degradation of I-LDL by L-DAN cells as a function of
125the incubation concentration of I-LDL is shown in figure 9.3.
At concentrations below 40 yg/ml the degradation rate rose sharply 
with increasing concentration. Further increase in the
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125concentration of I-LDL led to a considerably less steep rise in
the degradation rate, which approached linearity above 70 ug/ml. In
the presence of a 20-fold excess of unlabelled IDL the degradation
of radiolabelled IDL was inhibited and degradation increased
125linearly with the incubation concentration of I-LDL. The slope
of this curve was similar to the terminal part of the degradation
curve obtained in the absence of unlabelled LDL. By subtracting the
125values for degradation of I-LDL in the presence of unlabelled 
LDL from the degradation values in its absence, a saturable curve 
with a maximal velocity at 70 ug/ml results, which probably
correspond to high affinity degradation sites.
. . 125High affinity binding sites for I-LDL can be demonstrated
in a similar manner (fig 9.3). The high affinity binding sites
125start to saturate above 100 ug/ml of I-LDL. Reciprocal 
Lineweaver-Burke type plots of 1/cpm per ug cell protein versus 
1/LDL (ug/ml) allow calculation of Vmax and Km for degradation (Vmax 
= 385 cpm per ug cell protein; Km = 23 ug/ml) and binding (Vmax =
133 cpm per ug cell protein; Km = 71 ug/ml).
9.4 Discussion /
125
I-labelled IDL was found to associate with monolayers of 
cultured human lung tumour cells by two processes, one of high 
affinity and one of low affinity. The high affinity association
appears to represent binding of IDL to specific receptor sites on 
the cell surface. This binding process exhibited saturation 
kinetics at low concentrations of the lipoprotein. The other 
process, designated low affinity uptake, may represent non specific
endocytosis since the uptake was proportional to the lipoprotein
concentration in the medium with no apparent saturation.
Daunomycin is extensively metabolised within the cells to 
daunomycinol by the cytosolic NADPH dependent reductase. This 
oocurs to a greater extent after exposure of the cells to free 
daunomycin, such that after 2 hours incubation, intracellular levels 
of daunomycinol exceed those of the parent drug by approximately 2 - 
fold. There is less metabolism of daunomcyin after treatment of the 
cells with LDL-daunomycin. So, despite the fact that total 
intracellular drug levels (daunomycin plus daunomycinol) are 
greater following incubation with free daunomycin, the cellular 
concentration of unchanged daunomycin is similar at each time point. 
This implies that the LDL-daunomycin complex inhibits or protects 
daunomycin from cytoplasmic reduction.
Daunomycin, like adriamycin, enters the cells by diffusion of 
the electroneutral molecule through the lipid domain of the cell 
membrane. It is a more lipophilic molecule than adriamycin and this 
is reflected in its higher degree of cellular uptake for similar 
concentration-time exposures. On the basis of total intracellular 
drug, there would appear to be greater drug uptake following 
treatment with free daunomycin. The LDL-daunomycin complex must
176
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first bind to LDL receptors on the cell surface before being 
internalised and degraded within lysosomes with release of the 
cytotoxic agent. There are a number of potential rate limiting 
steps in this sequence which could serve to limit uptake of LDL- 
encapsulated daunomycin, relative to diffusion of free daunomcyin 
through the cell membrane.
The monolayer clonogenic cell survival curves for daunomcyin 
and LDL-daunomycin are similar. Daunomycin has considerably greater 
cytotoxic efficacy than daunomycinol (Bachur, 1979), and one would 
therefore expect that intracellular daunomycin levels would 
correlate with clonogenic cell kill. Despite the differing degrees 
of drug metabolism, daunomycin levels were virtually identical 
regardless of its mode of presentation to the tumour cells, and this 
could account for the similar clonogenic cell survival curves.
Although the mechanisms for transmembrane transport were
different, the subcellular distribution of daunomycin, demonstrated
by fluorescence microscopy was indistinguishable, whether free or
carrier bound daunomycin was used. The drug was bound to the
nucleus, the nuclear membrane and was distributed within the
cytoplasm in a granular fashion. It has been demonstrated (Egorin
et al,1984) that subcellular organelles cause differential
fluorescence quenching of bound daunomycin and therefore fluoresence
microscopy remains a useful but rather insensitive method for
determining the subcellular distribution of anthracyclines. Iwanik
et al, (1984) examined the subcellular localisation of daunomycin by
membrane subfractionation of P388 cells after incubation with 
125I-LDL-daunomycin or free daunomycin they noted that 
approximately 50% of free daunomycin and about 70% of LDL-daunomycin
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was associated with the membrane - organelle fraction of the cell,
with the remaining percentage being either loosely bound or located
125within the cytoplasm. The I-labelled fragments of LDL were 
especially enriched in plasma-membranes, microsomal-lysosomal- 
mitochondrial membranes and the insoluble nuclear pellet. In 
contrast to daunomycin derived from LDL, free daunomycin showed a 
strong preference for localisation in the insoluble nuclear pellet. 
Various other workers (Egorin et al, 1980; Gagliardi et al, 
1980; Noel et al, 1978), using different tumour monolayer systems 
suggest an enrichment of daunomycin in nuclei and/or lysosomal 
organelles. We were unable to quantitate binding in our study, yet 
the results of the experiments based on fluorescent localisation are 
in broad agreement with the authors quoted (Egorin et al, 1980) 
given the relative insensitivity of our method.
Despite identical monolayer cytotoxicity, LDL-daunomycin 
induced prolonged spheroid growth delay and greater clonogenic cell 
kill compared to free daunomycin. This was apparently associated 
with a greater degree of spheroid penetration by LDL-associated 
daunomycin. It has been demonstrated previously that enhanced drug 
spheroid penetration tends to be associated with perturbed growth 
kinetics of the spheroid. However, the lipophilic drugs and 
vehicles used previously to improve spheroid penetration were 
associated with altered kinetics of drug uptake in monolayer. 
For example, Brij 30 increased adriamycin uptake by 2 - 3 fold
and 4'-deoxy was taken up to a far higher extent than adriamycin
by virtue of its lipophilicity. This is not the case with LDL
associated daunomycin, where intracellular parent drug levels 
are identical to those obtained with free adriamycin. It is 
speculative, but Iwanik et al, (1984) did demonstrate a
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higher degree of membrane association of daunomycin following 
treatment with LDL-daunomycin and this could result in a more 
available, easily-transportable form of the drug which would diffuse 
more readily towards the centre of the spheroid. Daunomycin which 
has intercalated into ENA is bound in a stable situation with a 
relatively long half life of dissociation, and would therefore be 
less able to diffuse from cell to cell.
Further experiments are reguired in vivo, probably in nude mice 
with human lung tumour xenografts, to examine the affinity of
i
LDL-drug complexes for tumour and normal host tissue, the 
comparative pharmacokinetics relative to free drug and if there is a 
differential tumouricidal effect. Nevertheless, these preliminary 
experiments imply that LDL-daunomycin complexes could be a realistic 
means of biological targetting of active cytotoxic drugs to tumour.
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FREE DAUNOMYCIN LDL-DAUNO
Intracellular drug 
5
Time (ng/10 cells)
(minutes) Daunomycin Daunomycinol
Intracellular drug 
(ng/10^  cells) 
Daunomycin Daunomycinol
0
15
30
60
90
0
4.8 + 0.41
5.2 + 0.49 
10.1 + 1.2
13.2 + 1.4
0
6.6 + 0.5
13.1 + 1.2
53.6 + 4.8
82.3 + 6.7
0
4.5 + 0.38 
7.1 + 0.62
10.4 +1.15 
13.9 + 1.4
0
6.7 + 0.52
16.2 + 1.72
41.8 + 4.3
58.5 + 5.1
Table 9.1 Intracellular levels of daunomycin and daunomycinol
following treatment of LDAN monolayers with identical 
concentrations (5 yg/rnl of daunomycin and LDL- 
daunomycin).
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Median
Drug concentration Growth delay
(ug/ml) (days)
Daunomycin
0 (control) 7.3 (6.8 - 7.5)
0.5 13.9 (11.2 - 14.6)
1 15 (14.0 - 16.7)
2.5 18.2 (17.6 - 19.3)
5 20.3 (19.1 - 21.5)
6.8 (5.1- 7.4)
14.2 (14.0 - 16.7)
17.2 (16.2 - 18.4)
20.9 (19.1 - 22.8)
24.3 (22.6 - 25.9)
Table 9.2 Spheroid growth delay following treatment with daunomycin 
or LDL-dauno at differing concentrations for 1 hour. The
growth delay was taken to be the time to reach x 10
original volume. The figures in brackets denote the 95% 
confidence limits around the median value.
LDL-Dauno
0 (control) 
0.5
1
2.5
5
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Intracellular Drug 
(ng/105 Cells)
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Figure 9.1 Intracellular uptake and metabolism of daunomycin after exposure to 
free drug (£) or LDL - associated drug (^)
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Figure 9. 2 Clonogenic cell survival for monolayers and disaggregated spheroids 
following exposure to daunomycin or LDL-daunomycin. Each point is 
the mean of 4 experiments and the vertical bar denotes 1 standard 
deviation.
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CHAPTER 10 /185
The association of gap junctional conrnunication with cytotoxic 
drug resistance and intercellular drug transfer.
10.1 Introduction
Cell junctions are defined as structurally specialised domains 
that are formed at regions of contact between two cells, to which 
both cells contribute a part. These junctions are subclassified on 
the basis of ultrastructure and serve a variety of functions; 
provision of structural links bewteen cells? conduits through 
adjoining cell membrane pairs; mediation of unidirectional 
propagation of electrochemical impulses from cell to cell? the means 
of sealing cells tightly together.
This chapter will examine the tumour biological significance of
gap junctional communication in human lung tumour cells in vitro.
During the last decade it has become apparent that gap junctions are
mediators of metabolic cooperation, or coupling, between cells,
Subak-Sharpe et al, 1969, demonstrated that mutant Chinese hamster
fibroblasts deficient in the enzyme inosinic guanylic pyro-
phosphorylase could not incorporate hypoxanthine into ENA when they
grew alone, but that they did so when grown in contact with
wild-type cells. The enzyme block in the mutant was bypassed by
nucleotidyl transfer from the wild type cells, presumably via gap
junctions. The structure of gap junctions has been reviewed by
Lowenstein (1981), and it is apparent that individual channels of
the gap junctions allow exchange of "small" molecules (mol weight <
900 daltons) with specific charge and shape configurations (fig
+ + ,
10.1) Substances such as cations (Na and K ) , cyclic AMP, 
inositol, purine nucleotides, uridine nucleotides, thymidine
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nucleotides, deoxycytidine nucleotides, glucose-6-phosphate and 
other small molecules required for the cells intermediary metabolism 
are known to diffuse freely through gap junctions.
The development of direct junctional communication represents 
an important evolutionary step towards formation of highly 
differentiated multicellular organisms, and small molecular transfer 
during embryogenesis develops long before complex hormonal or 
electrical communication. Gap junctions have been demonstrated in 
many different types of tumour but their function or possible 
contribution to maintenance of the malignant phenotype remains 
unknown.
Dertinger and his co-workers (Dertinger and Hulser, 1981; 
Dertinger, Hinz and Jakobs, 1982? Dertinger, Guichard and Malaise, 
1983? Dertinger, Guichard and Malaise, 1984) have studied the 
phenonomen of contact resistance in Chinese hamster ovary spheroids. 
Contact resistance is the relative radioresistance to X -irradiation 
of cells grown as spheroids rather than as monolayer. These 
authors have speculated that contact resistance may arise from some 
functional differentiation occuring in gap junctionally coupled 
cells.
Nederman, Acker' and Carlsson (1981) have showed that 
5-fluorouracil penetrates human glioma and thyroid tumour spheroids 
efficiently within a few minutes, whereas vinblastine requires 
several hours to achieve a similar degree of penetration. Existing 
data indicate that for mammalian cells, the translocation of purine 
and pyrimidine nucleosides across the cell membrane is a combination 
of carrier-mediated transport and passive diffusion. One would
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expect that 5-fluouracil would pass from cell to cell via gap 
junctions given its molecular size and this could represent a 
relatively rapid mode of intercellular transfer.
In this chapter, the relationship between gap junction 
formation in tissue culture systems and cytotoxic drug resistance 
and transport is examined.
10.2 Materials and Methods /188
Monolayer and spheroid culture - the conditions of LDAN culture
have been previously described. The agar underlay technique was 
used in a similar manner to grow spheroids from two Chinese hamster 
ovary lines (DON and D0N6). The mutant (D0N6) differs from the 
parent line (DON) only in that it does not form gap junctions in 
tissue culture.
Determination of gap junction formation
5Recipient cell cultures were prepared by plating 1 x 10
cells in 2 ml of F10-DMEM medium into 3.5 cm Petri dishes each
containing 4 sterile glass coverslips (13 mm in diameter) and
incubating at 37 °C over night. Donor cell cultures were prepared
5by plating 2.5 x 10 cells in 5 ml of medium in 5 cm Petri dishes 
and incubating at 37 °C in a humid environment overnight. The
3
donor cells were then labelled by adding 50 pCi (5- H) uridine to
the medium and replacing in the incubator at 37 ° for 3 hours.
3Residual H-undine was removed by washing the donor cells 3 times 
with 5 ml of ice cold PBS. Donor cells were then detached by
rinsing with trypsin and resuspended in 2 ml of medium. To each 
dish of recipient cells, 200 pi of the labelled donor cells were 
added and the mixture co-cultured for 1 hour and 3 hours.
Following co-culture, the medium was removed, the cells washed 
twice with 2 ml PBS and then fixed with 2 ml of formol saline for 30 
minutes at room temperature. The coverslips were placed in racks 
and the acid soluble nucleotides removed by washing twice with 5% 
(W/Vj TCA at 4 °C for 2 minutes and then rinsed twice in distilled 
water. The coverslips were finally rinsed in ethanol and dried 
before being mounted, cells uppermost, with DPX on microscope slides 
and processed for autoradiography.
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DON and DON6 spheroids, approximately 600 ym in diameter, were 
exposed to H^“(7)-5-fluorouracil 50/uCi for 30 minutes at 37°C.
The spheroids were allowed to sediment, the radioactive medium 
removed, and they were then washed twice with ice cold PBS. The 
spheroids were then transferred into gelatine capsules containing 
OCT embedding gel and frozen in liquid N£. Thin sections (5um)
were then cut in a cryotome and mounted on microscope slides before
being processed for autoradiography.
Autoradiography
Ihe slides were dipped in Ilford ^  emulsion (1 part
emulsion; 2 parts water) at 45°C, dried under a stream of cold air 
and placed in a light tight box at 4°C. For grain counting, the 
autoradiographs were exposed for up to 7 days, for photography, they 
were exposed for up to 1 month.
After the exposure period, the slides were developed with Kodak 
D19 developer at 20°C for 5 minutes washed in water for 2 minutes
and then fixed for 4 minutes with Ilford Hypam Fixative. After
washing for 5 minutes in running water the cells were stained with 
freshly diluted giemsa (5% W/V in water) for 30 seconds. After a 
further wash, the slides were air dried and a second coverslip 
mounted on top with DPX.
Chemosensitivity Assay
The in vitro sensitivity of five different human lung tumour 
lines was established. The cell lines were established from 
individual cases of human lung cancer and their characteristics are
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summarised in table 10.1. The drugs used in the study were 
adriamycin, actinomycin D (trade name "Lyovac Cosmegen” Merk Sharp 
and Dohme International, Rahway, NJ, USA), VP16-213 (trade name 
"Vepesid", Bristol Myers Pharmaceuticals, Slough, UK), 
5-fluorouracil (Roche Products Lts, Welwyn Garden City, UK), 
melphalan (trade name, ’’Alkeran", The Wellcome Foundation Ltd, 
London, UK) and mitomycin C (Martindale Pharmaceuticals Ltd, Essex,
UK). They were diluted according to manufacturers instructions for 
injections and stored at -20°C until required. They were then 
further diluted in culture medium to the required concentrations.
In the case of melphalan, care was taken to ensure that these 
operations were carried out within 30 minutes because of the 
instability of the drug. In no case did the volume of diluent added 
with the drug exceed 1% of the final volume. Drug sensitivity 
assays were carried out using a modification of a method described 
previously (Morgan et al, 1983). Exponentially growing cells were 
trypsinised and seeded into 96 - cell Linbro microtitration platers 
to give 10 cells per well. After 3 days the medium was removed 
from the plate by suction and replaced by fresh drug free medium. 
After a further 24 hours, serial dilutions of the drugs were added 
to duplicate wells in the plate. Two wells of each roto were left 
free of drugs to act as controls. The drug-containing medium, was 
replaced with fresh drug containing medium after 24 and 48 hours 
during a total exposure to drugs of 72 hours. The drug containing 
medium was then replaced with drug-free medium and the cells were 
allowed a recovery period of 5 days with medium changes after 3 and
4 days. The viability of cells remaining in each well was 
determined by isotopic precursor incorporation into protein as 
described below. This technique has been previously demonstrated to 
produce equivalent results to cloning for the lung tumour cell 
lines.
In all drug experiments, cell counts (using a model ZB, Coulter
Counter) were made of replicate plates of each cell line to
determine population doubling time and to ensure that the control
cultures remained in exponential growth throughout the period of
drug-treatment and recovery. The period of drug exposure of 72
hours exceeded one population doubling time with all the cell lines
used in these experiments.
At the end of the experiment, cell number was assayed by
35exposing the cells to medium containing 3 .<iCi/ml [ S] -
methionine (specific activity 638-1275 Ci mmol "V or 1/uCi/ml L-4,
3 -15 [ H] leucine (specific activity 10 mCi mol ) for periods of
between 4 - 24 hours. During this period the rate of
incorporation of labelled amino acid has been shown to be linear 
(Morgan et al, 1983). The plates were then washed and cell protein 
(solubilised in 1M NaOH) counted as previously described. The 
incorporation of labelled amino acid of each well was expressed as a 
percentage of the control in that row and the doses of drug that 
inhibited protein synthesis by 50% (the ID5 q) was determined.
10.3 Results /
192
Gap junction formation
Typical autoradiographs are shown in fig 10.2. It is possible, 
as previously described, to quantitate the number of donor cells 
forming gap junctions with the recipients. The results for 
individual cell lines are shown in table 10.2.
Chemosensitivity of human lung tumour cells in culture
The respective ID^'s for each cell line and drug are 
tabulated (table 10.2). There is considerable variation in the 
sensitivity of individual cell types to different drugs. The ID^ 
values for individual drugs and the percentage of cells forming gap
junctions have been ranked from 1-5. The cell line forming most
gap junctions is ranked 1, and the cell line with the highest ID^q 
(i.e. cell line which is most resistant to that drug) is similarly 
ranked 1. This data is summarised in table 10.3. Using the non 
parametric Spearman Rank Correlation Coefficient, there is a
significant (p < 0.05) direct correlation between gap junction
formation and ID^ q (fig 10.2).
3Spheroid autoradiographs with [ H]-5-fluorouracil
The autoradiographs for DON and DON6 spheroids show that
the silver grains are evenly distributed throughout the DON 
spheroids, but are limited to an external annulus in DQN6 spheroids, 
implying limited drug penetration.
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10.4 Discussion
There is preliminary evidence to suggest that the ability to 
form gap junctions in tissue culture is related to cytotoxic 
chemosensitivity. The greater the ability of the cells to form gap 
junctions in vitro, the greater their resistance to a variety of 
antineoplastic agents. The evidence for this is indirect in that 
there is a statistically significant correlation between the two 
variables. It is important to realise that the existence of a 
correlation between 2 variables does not signify a cause/effect 
relationship, as gap junction forming ability could be an indirect 
"marker" of some other cellular function which is the determinant of 
anticancer drug sensitivity. Nevertheless, in view of the finding 
of Dertinger and co-workers on the relationship of contact 
resistance and radiosensitivity it is tempting to speculate that gap 
junctional communication could play a role in cytotoxic drug 
resistance.
At the very least, gap junctions determine that small molecules 
will diffuse between cells according to concentration gradients 
which implies that interconnected cells will have "egulibrium" 
levels of small diffusible molecules. If a toxic stimulus impinges 
locally on this diffusely connected cell network, with loss or 
alteration in the concentration of a vital biochemical component, 
then there would tend to be an alteration in the "intercellular 
equilibrium". This this way the healthy or unaffected cells could 
replace vital biochemical components or remove toxic products from 
damaged cells in such a way as to minimise the effects of the toxic 
stimulus at its site of application.
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The most elementary function of the gap junction is probably 
equilibration of concentration differences of channel permeant 
molecules between tissue cells which creates the bases for tissue 
homeostasis. Such a mechanism could account for a degree of 
cytotoxic drug resistance, if the permeant molecules had some role 
to play in genesis of their antineoplastic effect.
Autoradiographic drug penetration studies with tritiated 
5-Fluorouracil imply that the drug diffuses more rapidly into 
spheroids which are coupled by gap junctions (DON) than those which 
do not form gap junctions (D0N6). These Chinese hamster ovary 
spheroids are identical in every respect other than their ability 
for junctional communication. One would expect that 5-Fluorouracil 
has the correct size and shape characteristics to be transported 
through gap junctions, and therefore possibly bypass the potentially 
rate limiting step of transmembrane diffusion/transport within the 
spheroid. A "snakes and ladders" • analogy would perhaps be 
appropriate as the drug could reach the spheroid centre rapidly by 
means other than the conventional one of diffusing from cell to 
cell. There is no relationship between chemosensitivity to 
5-fluorouracil and gap junction formation in monolayer (table 10.3). 
Cells in monolayer exposed to drugs have approximately 50% of their 
cell surface area in direct contact with the drug containing 
solution therefore drug access, other than for the effect of 
membrane limited diffusion, is not a problem. In order to determine 
whether improved drug penetration via gap junctions altered the 
cytotoxic response of spheroids, the efficacy of 5-fluorouracil in 
DON and DON6 monolayers could be compared against a spheroid 
cytotoxic endpoint.
From these preliminary studies, it is apparent that gap 
junctional communication could be associated with cytotoxic drug 
resistance, although the underlying mechanism is not known, and that 
gap junctions could provide an intercellular conduit for cytotoxic 
drugs with appropriate size and shape characteristics.
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CELL LINE
Calu-3
SK-MES-1
L-DAN
WIL
A549
PATHOLOGY
Adenocarc inoma
Squamous carcinoma
Squamous carcinoma 
Adenocarcinoma 
Bronchiolo-alveolar 
carcinoma
SOURCE
American Type Culture Collection, 
U.S.A.
American lype Culture Collection, 
U.S.A.
Medical Oicology, Glasgow, UK 
Ludwig Institute, Sutton, UK
American Type Culture Collection, 
U.S.A.
Table 10.1 Non small cell lung cancer lines used in the gap 
junction study.
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hydrophilic
channel
Figure 10.1 The McNutt-Weinstein Model: An interpretation of the 
ultrastructure or the gap junction (left). The 
junctional membranes (M^  and M ) are shown pulled down 
to demonstrate the appearance of foot processes that 
normally project from each membrane and meet in the 
extracellular space at the midline (right). Aspects 
of the gap junction are shown as they appear in freeze- 
fracture replicas. Intermembrane particles, which 
partially (? or completely) span the junctional 
membranes are present on the A face. The inset 
illustrates an interpretation of the position of 
hydrophilic channels within the gap junction. These 
channels may provide the structural basis for low- 
resistance electrotonic coupling of neighbouring cells. 
The model is not drawn to exact scale. Reprinted from 
McNutt and Weinstein (1970), with permission of the 
Rockefeller University Press.
Donor Cell
Figure 10.2 Autoradiographs showing the distribution of 
3H-uridine in cells that
A. Form gap junctions B. Do not form gap junctions
(magnification x 100)
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Rank for 
Gap Junctions
4
1 2 3 4 5
Rank for 
Drug Resistance
Figure 10.3 Correlation between gap junction formation and cytotoxic drug
resistance (r = 0.63, p<0.05). Dots which are grouped together 
represent single point repeats.
CHAPTER 11 / 202
A concentration-effect model for spheroid drug diffusion
11.1 Introduction
A considerable amount of information is available on the 
pharmacokinetics of anticancer drugs, but much less is known of 
their pharmacodynamics, that is of the relationship between 
therapeutic or toxic response and drug concentration. The 
pharmacodynamic aspect of quantitative pharmacology attempts to 
relate drug concentration at the receptor site to biological 
response. Since the drug concentration at the receptor site can 
rarely be measured directly, it is more usual to measure the drug 
concentration in plasma and assume that it reflects receptor site 
concentrations indirectly.
Powis (1985) has recently reviewed the relationship of tumour 
response to a number of pharmacokinetic parameters governing 
anticancer drug disposition, such as peak drug concentration and the 
area under the plasma concentration-time curve (AUC). He noted that 
there are no studies relating parameters of tumour response in vitro 
to those in vivo. It is apparent from the preceeding data presented 
in this thesis that the multicellular spheroid would appear to be a 
better predictive model in vitro than monolayer. In the initial 
part of this chapter a mathematical concentration-effect model is 
presented which attempts to quantitate and correlate in vitro/in 
vivo tumour clonogenic survival.
In addition, it has been possible to design a mathematical 
model which predicts spheroid clonogenic cell survival on the basis 
of drug diffusion gradients. The model is described with supportive 
experimental details.
11.2 Materials and Methods
Concentration-Effect Model
Clonogenic cell kill in monolayers, spheroids and xenografts of 
MGH-UI human bladder carcinoma cells in response to adriamycin 
treatment has been described by Erlichman and Vidgen (1984). This 
is a unique set of information in that they have adriamycin 
sensitivities for the same cell line grown at 3 different levels of 
complexity (monolayer, spheroid and xenograft) assessed by a common 
cytotoxic assay. The xenografts were dissociated at intervals 
following treatment, and clonogenic cell survival was measured, 
rather than using tumour growth delay as a cytotoxic end point.
The monolayer and disaggregated spheroid clonogenic cell 
survival curves were redrawn as % cells killed Vs log adriamycin 
concentration (fig 11.1) in order to convert them to recognisable 
standard dose-response curves.
The EMax model, developed by Langmuir and modified by Hill was 
adapted for use (Goodman and Gilman, 1975) as follows;
If, n[D] + [R] ^  [nDR]
Where [D] = number of drug molecules 
[R] = number of free receptors 
[DR] = drug/receptor complex
n = number of drug molecules reacting with 1 receptor, 
then it can be shown that 
E = [C] Emax 
[c50] + [C]
Where E = observed effect (% clonogenic cell kill)
Emax = maximum possible response
n = number of drug molecules reacting with 1 receptor 
At E= 1/2 Emax, [C] = [C5q]
C = drug concentration in plasma.
The assumptions on which this model is based, include;
E [DR] and that the system is in equilibrium.
The dependence of cytotoxic response on both the concentration 
and duration of drug exposure has already been documented (sec 2.3). 
In view of these findings the cumulative AUC for total drug exposure 
in monolayer, spheroid or xenograft has been entered in the 
concentration-effect model rather than instantaneous plasma 
concentration as this is more likely to bear a quantitative 
relationship to tumour response. It must be emphasised that most 
concentration-effect modelling hitherto has concentrated on acute 
effects eg relating drug levels to instantaneous changes in blood 
pressure, heart rate, electrocardiographic parameters etc, rather 
than delayed or chronic response experiments such as tumour growth.
The paramacokinetics of adriamycin in nude mice bearing tumour 
xenografts has been described (sec 7.3) Sheiner (1982) has devised a 
compartmental model to relate some estimate of plasma concentration 
to effect. The properties of the effect compartment (vide infra) 
are defined as follows.
1. The amount of drug in the effect compartment is governed by 
first order processes.
2. The amount of drug in the effect compartment is relatively 
small.
3. The measured effect is related to the drug concentration in 
the effect compartment.
The compartmental model can be described graphically as 
follows.
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Intravenous
CENTRAL PERIPHERAL12
'21
v  ie10
EFFECT COMPARTMENT
eq
This model accounts for drug distribution into 2 compartments.
D is the dose of drug administered by intravenous bolus. is
the amount of drug in the central compartment; is the amount of
drug in the peripheral compartment; X_ is the amount of drug in
the effect compartment. The microscopic rate constants governing
in ter compartmental drug transfer are YL^ and r whereas
is the excretion rate constant K. and K are the rateie eq
constants defining the effect compartment.
By a series of Laplace transforms (Gibaldi and Perrier, 1975) 
it is possible to deduce that
v  ^ ~ -keqtx „ ' , -Bt -keqtx
E “ A’V1 ie > + B V K (e - e )
( K. - «*. ) eq (Keq “ P>
Where, B = Kgl K10
oc + B -  K i o  + Ki2 + K21
A + B = dose/V.
= volume of the central compartment
X = the amount of drug in the effect compartment. 
E
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By using the compartmental model to calculate the amount of 
drug in the effect compartment of the basis of plasma drug levels it 
is then possible to work out the cumulative AUC of drug in this 
compartment. This value can then be used in the Emax model derived 
from the monolayer and spheroid in vitro data.
The % cell kill v log concentration curves were fitted to 
asymptotic sigmoid curves by the method of least squares using an 
"in-house" programme based on the Marquhardt alogorithm (Bevington, 
1978).
This approach allowed calculation of Emax and [C^ q] for 
adriamycin in monolayer and spheroid culture systems. The murine 
adriamycin plasma profiles were fitted to the compartmental effect 
model using non linear least squares as above. It was possible to 
derive X„, the amount of drug in the effect compartment, using 
these programmes. The cumulative AUC's were calculated by the log 
trapezoidal rule. The calculated effect (clonogenic cell kill) was 
then compared with the actual xenograft clonogenic cell kill found 
by Erlichman and Vidgen.
Spheroid drug penetration model
A mathematical model of spheroid drug penetration and its 
relationship to cytotoxicity was developed to facilitate comparison 
of actual with "ideal" drug penetration. A number of variables 
which would be expected to have some bearing on intact spheroid cell 
sensitivity have been included as model parameters; the gradient of 
drug diffusion (variable); the degree of cell kill per unit of drug 
exposure (fixed); the cell cycle specificity of the drug (fixed) 
the cell cycle kinetics of the spheroid cells and their variation 
with spheroid depth (fixed).
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The descriptive mathematics are simple and are based on the 
assumption that the spheroid is a perfect sphere made up of a series 
of concentric annuli (fig 11.2). The sphere consists, arbitrarily 
of ten annuli whose volume is described by the formula 2 TT fa (R= 
mean radius of annulus; A= the area of cross section of annulus)•
Annular volume is directly proportional to cell number, assuming a 
constant cell volume. A given drug exposure, in arbitrary units 
will produce a consistent degree of cell kill (8% cell kill
per unit drug exposure for cycling cell; 2% cell kill per unit
drug exposure for non cycling cells). It is assumed that drug 
exposure within a separate annulus is homogeneous.
A number of computer simulated gradients for drug diffusion and 
the variation of cell cycle kinetics with spheroid depth were 
constructed (fig 11.3). The gradient for cell cycle kinetics was 
fixed at that which conformed most closely to the experimental data
(vide infra) . The only variable which was not fixed was the drug
diffusion gradient. The % cell kill associated with each of the 
hypothetical gradients shown in figure 11.3 was calculated. The 
derived formula for the degree of cell kill within a spheroid 
annulus was;
%cell kill = D V C 
Where D = units of drug exposure 
V = annular volume
C = cytotoxic dose correction factor for the proportion 
of cycling cells per annulus.
Determination of intraspheroidal gradients in drug diffusion and the 
proportion of cycling cells
Selective disaggregation of spheroids has been described by 
Wibe (1981) and Kwok and Twentyman (1985). Their method has been
modified for use with L-DAN spheroids. Twenty spheroids of 
approximately 350 urn in diameter were placed in a race track Petri 
dish (external diameter, 5 cm, internal diameter 3 cm). The culture 
medium was removed and replaced with 3 ml of 0.125% trypsin. The 
spheroids were incubated at 37°C with intermittent agitation. 
After 20 minutes, 3 ml of ice cold medium containing 10% foetal calf 
serum was added to inactivate the trypsin. After gentle pipetting 
the spheroid cores were allowed to sediment and the medium contining 
disaggregated cells was removed and the cells counted in a Coulter 
Counter. The residual spheroid cores were reincubated with 0.125% 
trypsin at 37°C for a further 20 minutes before the reaction was 
stopped by addition of fresh ice cold medium. The spheroid cores 
were then disaggregated by gentle pipetting to a single cell 
suspension prior to counting. Using this method it was possible to 
strip 40-45% of spheroid cells from the external surface. Using the 
televisual image analysis system (sec 3.2) it was possible to follow 
changes in size and shape of individual spheroids in filter wells, 
following treatment with adriamycin. If spheroids were treated for 
longer than 20-25 minutes with 0.125% trypsin, then in some 
instances the diameter of the spheroids increased. Prior to this 
there was relatively uniform slight diminution in diameter which 
varied directly with the duration of trypsin exposure. Presumably, 
with prolongation of trypsinisation beyond 20-25 minutes, there is 
an alteration in the 3 dimensional geometry of the spheres and they 
adopt a disciform shape. This would explain the apparent increase 
in diameter despte fewer component spheroid cells. It would be 
impossible to determine in that situation if disaggregated cells 
came from peripheral annuli or the spheroid core. Trypsinisation
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was therefore limited to 20 minutes and produced 2 cell populations 
- external (probably corresponding to the 2 outermost annuli) and 
internal (corresponding to the remainder of the spheroid core). 
Intracellular drug levels were characterised following exposure
washed, differentially trypinised and the external/internal cell_
analysis as previously described (sec 2.2).
The cell cycle kinetics of the two populations were assessed by
flow cytometry following differential trypinisation. The cell
suspension was treated enzymatically to produce a suspension of cell
nuclei thus eliminating non specific cytoplasmic fluorescence.
After washing in phosphate buffered saline, the nuclei were stained 
-5with 2.5 x 10 M ethidium bromide m  tris-EDTA buffer (with a
molarity of 395 mOsmoles); this high molarity further reduces the
risk of non specific binding of ethidium bromide. The ENA contents 
of the cell nuclei were then analysed using a rapid flow 
cytofluorometer (Becton-Dickinson FACS II cell sorter) with a flow 
rate of up to 1,000 cells/minute. Excitation and emmision 
wavelengths were 455-490 nm and 590-630 nm, respectively. The
machine output was sorted with a 256 multichannel analyser. The
number of cells in G^ , S and G^M phases was then calculated.
to adriamycin for 1 hour. The spheroids were treated,
populations were separated and stored at -20°C until drug
11.3 Results / „,«
' 210
Concentration - Effect Model
The cell kill vs log concentration curves were fitted by least 
squares to yield the Hill parameters, Emax and C5Q (fig 11.1).
The sigmoid curves for monolayer and spheroid are parallel, 
with a shift to the left for spheroids along the concentration axis. 
The Emax values are similar (spheroid = 99.99%; monolayer = 99.99%) 
whereas the values reflect the axial shift (spheroid =3.2
/jg/ml; monolayer = 1 /ig/ml).
The plasma concentration-time profile for adriamycin in tumour 
bearing nude mice (fig 7.2) has already been described. The data 
was fitted to the concentration-effect model and the cumulative AUC 
for the effect compartment was derived. Erlichman and Vidgen (1984) 
disaggregated the MGH-UI xenografts and measured clonogenic cell 
survival following treatment with adriamycin, at 2 hours and 18 
hours therefore the cumulative AUC at 2 and 18 hours was calculated. 
The relationship between clonogenic cell survival and the cumulative 
AUC for monolayer, spheroids and xenografts is shown in figure 1.4.
As there is a common expression for drug exposure (cumulative 
AUC), this allows direct comparision of the effects of adriamcyin on 
each model system, as assessed by a common cytotoxic end point. 
Spheroid clonogenic survival would appear to be a better predictor 
of clonogenic survival in vivo than monolayer.
By substituting the Emax and C ^  values for monolayer and 
spheroid in the modified Hill equation with the appropriate drug 
concentration from the effect compartment it is possible to 
calculate the expected effect (clonogenic cell kill)•
The actual and predicted clonogenic cell kill following 
intraperitoneal administration of 20 mg/kg adriamycin is shown in 
table 11.1.
Again, the values predicted from the spheroid model are 
significantly closer to the reality governed by drug distribution 
and penetration in vivo than the monolayer derived figures. 
Spheroid penetration model
Intracellular adriamycin levels (mean + standard deviation)
were significantly higher (p < 0.001) in the external spheroid cells 
5
(5 + 2.1 ng/10 cells) compared to the internal cells (0.8 + 0.15
5
ng/10 cells). There was no evidence of drug metabolism by the 
external cells, however approximately 5% of intracellular adriamycin 
was converted to the 7-deoxyaglycone of the parent drug in cells 
from the interior of the spheroid.
Fluorescent microscopy demonstrated that adriamycin did not 
diffuse into the centre of the spheroid at drug concentration and 
exposures used. On this basis, the computer simulated drug 
diffusion was fitted to the experimental data and constrained to go 
through zero at the spheroid centre. Of the computer simulated 
diffusion gradients (figure 11.3), number 5 is closest to the 
experimental data. The expected clonogenic cell kill for each 
gradient assuming constant annular cell sensitivity and cell cycle 
kinetics, is summarised in table 11.2. As is obvious, the best 
results in respect of clonogenic cell kill were achieved with the 
homogeneous drug distribution (gradient 1) and the worst with the 
gradient most representative of the experimental data (gradient 5).
Cognisance must be taken, however, of the cell cycle phase of 
cells in different annuli. Differential sensitivity of 
expononential and plateau phase cells to adriamycin has already been 
demonstrated (sec 3.3). The cell cycle state of cells from the two 
different regions was different (p < 0.01); external layer,
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phase 62+15%, S phase 28+14% and G2  phase 10+5%; internal core,
G^ phase 80 + 18%, S phase 15 + 6% and G2  phase 5 + 3%. It is 
likely that the G^ population of cells increases towards the 
centre of the spheroid, and that a cellular subpopulation exists 
with G^ phase ENA content yet with a low ENA content (Alison et 
al, 1983). These cells are Gq cells and most resemble the 
relatively resistant plateau phase cells in monolayer. The 
experimental data (in concert with published data on the relative 
percentage of G^ cells with low RNA levels in the spheroid core, 
Allison et al, 1983) was fitted to cell cycle kinetic gradient. The 
effect that inclusion of the cell cycle sensitivity factor has on 
spheroid clonogenic cell kill has been calculated for the 
homogeneous and monoexponential drug diffusion gradients (table
11.3). Despite considering this factor, homogeneously distributed 
drug still produced approximately twice the cell kill that the 
exponential gradient did.
11.4 Discussion /
These relatively simple models have been presented for two 
reasons
1. to illustrate that a concentration-effect relationship 
between in vitro and in vivo drug sensitivity testing can 
be devised.
2. to demonstrate the major differences in cytotoxicity in a 
spherical tumour mass between homogeneously and 
non-homogeneously distributed drug.
The concentration effect formulae predict that the multi- 
cellular spheroid would be a better model in vitro than monolayer 
for assessing a drug's activity in vivo, at least in mice.
There is little doubt that clinical oncologists would like to 
have available to them a reliable system of predictive chemo­
sensitivity testing. The facility of sending to the laboratory a 
small piece of tumour tissue from a readily accessible site and 
receiving back within a few days a statement of which of a panel of 
cytotoxic drugs will kill a high proportion of the malignant cells 
present in the sample, at clinically achievable drug exposure 
levels, would radically alter the basis of current chemotherapeutic 
practice. Current methodology includes clonogenic assays, medium 
term assays using cell culture and short term biochemical assays. 
Clonogenic assays have been most widely used, however, there are 
theoretical and pragmatic problems with this approach which have 
been well reviewed by Sellby, Buick and Tannock (1983). The use of 
multicellular spheroids in such systems has not been adequately 
assessed. Jones et al (1982) examined tumour cells from 7 patients 
with ovarian cancer and from 22 different human tumour xenografts 
(representing a wide range of histological subtypes) for 
multicellular spheroid forming ability. Spheroid formation was
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limited to cells derived from xenografts. Volume growth delay was 
used as an end point and differences in spheroid response broadly 
reflected patient and in vivo xenograft response. Their data 
suggests that spheroid formation from human tumour material does not 
occur with the same freguency and readiness as spheroid formation 
from established in vitro cell lines. This may represent a major 
drawback to the use of spheroids in routine chemosensitivity 
predictive assays.
The spheroid model could be used in preclinical drug 
development, as it could differentiate which amongst many cytotoxic 
analogues goes forward for testing in murine models. This would 
have the dual advantages of economic and simple analogue screening.
It is virtually impossible to rank in vivo cytotoxic drug 
efficacy on the basis of in vitro sensitivity testing. Although it 
is possible to derive terms such as the ID^q or ID^ for
individual drug exposures in vivo. Using concentration-effect 
relationships such as the one described, it should be possible to 
marry in vitro data with the drugs known pharmacokinetics and rank 
drug efficacy in this way.
The geometric drug diffusion model was constructed in such a 
way as to allow comparison of ideally distributed drug with a
theoretical curve for drug diffusion which corresponded most closely 
to the experimental situation. A series of fixed assumptions was 
made and the drug exposure gradient was varied. Homogeneously
distributed drug was associated with an approximately two-fold 
greater degree of cell kill than poorly penetrated drug. The model 
presented has been spherical but this could be modified to
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cylindrical conformations, more in keeping with drug diffusion from 
the tumour vasculature (fig 11.3). It is important to recognise, 
however, that the surface area/volume characteristics of a cylinder 
are markedly different from those of a spheroid and therefore a 
different relationship between drug penetration and effect would 
exist.
It is interesting to note that there was a small but 
easily detectable degree of metabolism of adriamycin to its 
7-deoxyaglycone. As mentioned previously (sec 4.4 ) this could
imply anaerobic bioreduction with free radical production. 
Dertinger, Guichard and Malaise (1984) have demonstrated significant 
gradients in oxygen diffusion into spheroids such that the central 
core, even in relatively small spheriods is quite hypoxic (external 
p0£ = 100 mmHg, central pC^ = 10 rrmHg). It is possible that the 
spheroid model would be appropriate for tumour drug metabolism 
studies in vitro, as it mimics the microenvironment of tumour in 
vivo, more closely than monolayer.
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Surviving Xenograft Clonogenic 
Fraction
(time of sacrifice after treatment)
2 hours 18 hours
Experimental data 
(Erlichman & Vidgen, 1984) 0.83 0.76 (actual)
Concentration-effect model 
(monolayer parameters) 0.74 0.37 (predicted)
Concentration-effect model 
(spheroid parameters) 0.9 0.65 (predicted)
Table 11.1 The actual and predicted xenograft clonogenic
surviving fraction according to the concentration- 
effect model.
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Figure 11.1 Dose-response curves for clonogenic cell kill vs
log drug concentration in MGtt-UI monolayers (O )
and spheroids (• ). This data was fitted by non
linear squares to a Hill-plot function to derive
Emax and C_._.bu
SPHEROID ANNUL1
Figure 11.2 Diagrammatic representation of spheroid annuli.
UNITS OF DRUG EXPOSURE
ExteriorCentreExterioi
SPHEROID ANNULUS
Figure 11.3 Arbitrary drug exposure (1-6) gradients from the spheroid surface to 
its centre.
/221
CHAPTER 12 
Clinical Relevance and Future Aims
In summary, it has been possible to overcome cytotoxic drug 
penetration barriers in a variety of in vitro and in vivo model 
systems, either by altering the physicochemical properties of the 
class of drugs under study, or by coadministering chaotropic agents 
which increase membrane permeability to the antineoplastic agent. A 
usual sequitur of enhanced penetration was ameliorated cytotoxicity.
The spheroid model would appear to be a better means for 
pre-clinical predictive testing of drug activity in vitro, than 
monolayer, as it has been shown that drugs with identical clonogenic 
survival curves for monolayer conditions, can differ significantly 
with regard to spheroid activity. The spheroid clonogenic response 
to adriamycin appears to be more closely related to tumour response 
in vivo, as defined by the concentration-effect model. This is, 
perhaps an area where further investigation might prove fruitful, 
with spheroid drug testing as part of a decision network for 
extended drug studies in vivo, especially if the analogue under 
study is a lipophilic derivative.
There are a number of clinical situations in which enhanced 
penetration would prove relevant. The aim of adjuvant chemotherapy 
is to eradicate clinically undetectable micrometastases after 
radiotherapeutic sterilisation or surgical debulking of the primary 
tumour. If we consider the spheroid an adequate model of a 
micrometastasis prior to vascularisation, then apart from problems 
related to drug distribution in vivo, there would be significant 
penetration barriers in tumour spheroids only a few hundred microns 
in diameter. It may well be that lipophilic anthracycline 
derivatives, which are otherwise equipotent in advanced disease, 
would be more efficacious than adriamycin. Cummings and McCardle
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(1986) have carried out a pilot study wherein they administered 
25 mg of adriamycin intra operatively and removed the primary breast 
tumour some 30 minutes later. Adriamycin levels were then measured 
within the tumour and surrounding normal breast tissue removed at 
mastectomy. Epirubicin a hydrophobic epimer of adriamcyin is 
undergoing clinical evaluation in advanced breast cancer in the- 
departments of Radiotherapeutics and Medical Oncology in Glasgow 
University. A study has been5 initiated to measure tumoural levels 
of epirubicin in breast cancer patients, as described. In addition, 
in collaboration with Dr G W Aherne, Department of Biochemistry, 
University of Surrey, an immunocytochemical stain based on 
the immunoperoxidase technique is being developed which will allow 
staining for intercalated adriamycin and epirubicin in formalin 
fixed breast tissue. It will therefore be possible to assess 
comparative penetration of adriamycin and epirubicin by dual 
methods; quantitative measurement of the amount of drug within the 
tumour; immunohistochemical demonstration of the pattern of 
anthracycline binding relative to the tumour vasculature.
Certain tumours have a propensity for metastasising to specific 
compartments within the body and often the metastases rather than 
the primary tumour produce morbidity. Cytotoxic agents tend to have 
steep dose response/toxicity curves which limits their systemic use. 
In this setting the concept of regional chemotherapy has undergone a 
renaissance over the past decade for several reasons; improved 
understanding of the pharmacokinetic principles governing regional 
drug administration; improved pump technology allowing safe and 
reliable drug perfusion; improved radionuclide imaging which allows 
determination of the degree of regional perfusion.
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Ozols et al (1979) • have described the failure of intra- 
peri toneal adriamycin to penetrate further than a few cell layers 
in solid ovarian tumour nodules in a murine model. Adriamycin has 
been tested clinically in patients with advanced ovarian cancer, 
with presumably similar problems with nodular drug penetration. 
Similarly, adriamycin has been extensively used by intravesical 
installation in patients with bladder cancer (Eksborg, 1983).
Pharmacological studies have shown that despite installation of 
therapeutic amounts of the drug (50 mg) that systemic absortion is 
minimal (Eskborg, 1983). This has been attributed to the relatively 
impermeant nature of the vesical wall, but one could imagine 
penetration problems both for tumour as well as normal vesical 
urothelium. Studies are planned to look at the tumour distribution 
(by fluorescent microscopy) of adriamycin and epirubicin following 
intraperitoneal (ovarian carcinoma) and intravesical (superficial 
bladder tumours) administration. These studies will be conducted in 
tandem with pharmacological studies and attempts will be made to 
correlate tumour penetration with systemic levels of the 
anthracycline. The evident drawback of using agents which might 
have a better penetration pattern, or co-administering adriamycin 
with surfactant, is that drug absorption from the corporeal cavity 
will be promoted and this will reduce the so-called regional 
advantage, codified by Dedrick et al (1978).
Nevertheless, improved drug penetration results in enhanced 
cytotoxicity and this would negate any regional disadvantage caused 
by increased systemic drug exposure.
Intrahepatic arterial administration of adriamycin loaded 
albumin microspheres is currently being investigated in the 
Departments of Medical Oncology and Surgery (Glasgow Royal 
Infirmary). Preliminary evidence suggests that these microspheres 
can be targeted to intrahepatic metastases following intra-arterial 
administration by co-infusing the vasoconstrictor, angiotensin II 
(Lewi et al, 1985; Kerr et al, 1986). It is possible that future 
regional infusion studies will include assessment of niosomes. 
Organ entrapment rates of niosomal particles and the pharmaco­
kinetics of adriamycin release would be examined.
Further studies are planned in the field of intercellular 
communication of cancer cells and its contribution to drug 
resistance. Coculture experiments between gap junction forming 
cells which are either resistant or sensitive to a particular 
cytotoxic agent will be performed. The different cell lines display 
different pheontypic markers which can be demonstrated by 
immunocytochemical staining. Therefore although equal cell numbers 
are co-incubated at a drug concentration which will virtually 
eradicate one cell type, but not the other, the percentage of the 
parent cells surviving can be quantified and compared with expected 
values from pre-existing drug sensitivity data.
Mutant Chinese hamster ovary cells which do not form gap 
junctions do form spheroids and have similar growth kinetics to the 
wild type cells. Radiobiological experiments are underway to 
determine whether the spheroids which form gap junctions (wild type) 
are relatively radioresistant.
A series of studies with cytotoxic drug-low density lipoprotein 
complexes are envisaged. In vivo experiments aimed at defining 
relative cytotoxicity and pharmacology of free and LDL-bound
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daunomycin in nude mice bearing lung tumour xenografts will be 
carried out. Further characterisation of the use of LDL as a 
biological targeting carrier can be done clinically. Radiolabelled 
LDL will be administered to patients which differing primary and 
metastatic tumours and it will be possible to determine tumoural 
uptake relative to normal tissues by external radionuclide 
scanning.
One of the major drawbacks precluding clinical used of 
LDL-daunomycin is the relatively small amount of drug incorporated 
per molecule of LDL. Scaling up calculations show that 
approximately 1 litre of plasma would have to be harvested from each 
patient to allow separation of sufficent LDL for a therapeutic dose 
of daunomycin to be subsequently given. This problem could be 
overcome by attempting to load LDL with more lipophilic drugs. A 
series of lipophilic cogeners of adriamycin and daunomycin is 
available from Farmitalia Carlo Erba Ltd. In this respect the 
cyano-morpholinyl derivatives are especially interesting as they are 
extremely lipophilic and extremely potent at low doses. Perhaps 
relatively little of these derivatives would need to be incorporated 
into LDL to maintain full potency.
Peterson et al, 1986, have demonstrated a significant inverse 
relationship between LDL receptor activity and survival in stored 
breast tumour specimens from patients who had undergone mastectomy.
We have access to stored tumour tissue from patients who have had 
gastric, breast and pulmonary tumours resected and adequate clinical 
follow up. Using a receptor binding assay it should be possible to 
investigate the use of receptor activity as an independent 
prognostic factor for each of these tumour types.
Ozols et at (1979) have described the failure of intra-
peritoneal adriamycin to penetrate further than a few cell layers in 
solid ovarian tumour nodules in a murine model. Adriamycin has been 
tested clinically in patients with advanced ovarian cancer, with 
presumably similar problems with nodular drug penetration. 
Similarly, adriamycin has been extensively used by intravesical 
installation in patients with bladder cancer (Eksborg, 1983).
Pharmacological studies have shown that despite installation of 
therapeutic amounts of the drug (50 mg) that systemic absorption is 
minimal (Eskborg, 1983). This has been attributed to the relatively 
impermeant nature of the vesical wall, but one could imagine 
penetration problems both for tumour as well as normal vesical
urothelium. Studies are planned to look at the tumour distribution 
(by fluorescent microscopy) of adriamycin and epirubicin following 
intraperitoneal (ovarian carcinoma) and intravesical (superficial 
bladder tumours) administration. These studies will be condicted in 
tandem with pharmacological studies and attempts will be made to 
correlate tumour penetration with systemic levels of the 
anthracycline. The evident drawback of using agents which might 
have a better penetration pattern, or coadministering adriamycin
with surfactant, is that drug absorption from the coporeal cavity 
will be promoted and this will reduce the so-called regional 
advantage, codified by Dedrick et al, 1978).
Nevertheless, improved drug penetration results in enhanced 
cytotoxicity and this would negate any regional disadvantage caused 
by increased systemic drug exposure.
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A number of questions have been raised by this thesis, 
therefore the work must be considered, in a sense preliminary, 
however, active investigation with a secondary series of experiments 
has already been initiated.
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